Cancer treatment with GM-CSF antagonists
Patent Information
- Application Number
- JP2023523033
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-10
- Filing Date
- 2021-10-26
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Tumor cells express inhibitory cytokines that evade host immunity, suppressing natural antigen presenting effector cell populations, and regulatory T cells are prevalent in tumor microenvironments, hindering effective immune responses against malignant cells.
Utilizing GM-CSF antagonists to inhibit the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) and enhance immune responses in cancers with mutations in KRAS, NRAS, JAK2, and/or PTPN11, potentially combined with immune checkpoint inhibitors (ICIs) to overcome immunosuppression and stimulate effector cells.
The use of GM-CSF antagonists leads to reduced PD-L1 expression on MDSCs, increased T cell proliferation, and enhanced immune responses, improving the effectiveness of cancer therapies, particularly in immune checkpoint inhibitor-refractory and terminal/metastatic cancers.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 105,773 filed on 26 October 2020, U.S. Provisional Application No. 63 / 120,319 filed on 2 December 2020, and U.S. Provisional Application No. 09 / 10 / 2021 filed on 10 September 2021, the contents of which are incorporated herein by reference in their entirety.
[0002] Sequence List This specification refers to the sequence listing (submitted electronically on October 26, 2021, as a .txt file named "KPL-035BWO_ST25.txt"). The .txt file was created on October 26, 2021, and is 21KB in size. The entire contents of the sequence listing are incorporated herein by reference. [Background technology]
[0003] Tumor cells express unique antigens that can be recognized by the host T cell repertoire, making them potent targets for tumor immunotherapy. However, tumor cells express inhibitory cytokines that suppress native antigens, evading host immunity and presenting effector cell populations. One element in this immunosuppressive environment is the increased presence of regulatory T cells found in tumor beds, efflux lymph nodes, and the circulation of patients with malignant tumors. One area of further research is the development of therapeutics to reverse tumor-associated anergies and stimulate effector cells to recognize and eliminate malignant cells. [Overview of the Initiative] [Means for solving the problem]
[0004] The present invention provides, in particular, an improved method for treating cancer using GM-CSF antagonists. The NRAS, KRAS, JAK2, and PTPN11 genes play a particularly important role in signaling pathways among other genes, and mutations in these genes are associated with various cancers. For example, KRAS is one of the most difficult targets in cancer. A single KRAS (Kirsten rat sarcoma virus oncogene homolog) mutation is present in up to 25% of all human tumors, making it one of the most frequently activated oncogenes. Despite more than 60 years since its discovery, researchers still struggle to block its variants. The present invention provides, in particular, an improved method for treating cancers having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11 using GM-CSF antagonists. The present invention is in part based on the surprising discovery that GM-CSF induces the expression of PD-L1 on MDSCs with immunosuppressive activity, and that this expression can be suppressed by antagonizing GM-CSF. The present invention also provides methods for treating cancer using GM-CSF antagonists in combination with other cancer therapies, as further described herein. The present invention further provides methods for treating chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) using GM-CSF antagonists.
[0005] In some embodiments, the present invention provides a method for treating cancer having a KRAS mutation, comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein the administration of the GM-CSF antagonist results in inhibition of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
[0006] In some embodiments, the present invention provides a method for treating cancer, comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein the administration of the GM-CSF antagonist results in inhibition of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
[0007] In some embodiments, the present invention provides a method for inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in patients with cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, the method comprising administering a GM-CSF antagonist to the patient.
[0008] In some embodiments, the present invention provides a method for inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in a patient with cancer, the method comprising administering a GM-CSF antagonist to the patient.
[0009] In some embodiments, the present invention provides a method for enhancing an immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the patient has cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, and the immune response is increased compared to a control.
[0010] In some embodiments, the present invention provides a method for enhancing the immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the immune response is increased compared to a control.
[0011] In some embodiments, cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11 is chronic myelomonocytic leukemia (CMML).
[0012] In some embodiments, cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11 is juvenile myelomonocytic leukemia (JMML).
[0013] In some embodiments, the immune response is the percentage of T cell proliferation. In some embodiments, the T cells are CD8-positive (CD8+). In some embodiments, the T cells are CD4-positive (CD4+). In some embodiments, the T cells are double-positive for CD8 and CD4 (CD8+ / CD4+).
[0014] In some embodiments, the control represents the level of immune response in patients before administration of a GM-CSF antagonist. In some embodiments, the control is a reference immune response level in control patients receiving cancer treatment without a GM-CSF antagonist, or a reference immune response level based on historical data.
[0015] In some embodiments, cancer therapy is immunotherapy.
[0016] In some embodiments, administering a GM-CSF antagonist increases the effectiveness of immunotherapy.
[0017] In one embodiment, the present invention provides a method for suppressing PD-L1 in patients with cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, the method comprising administering a GM-CSF antagonist to patients requiring treatment compared to a control.
[0018] In one embodiment, the present invention provides a method for suppressing PD-L1 in cancer patients, comprising administering a GM-CSF antagonist to patients requiring treatment compared to a control.
[0019] In some embodiments, administering a GM-CSF antagonist reduces PD-L1 levels in patients.
[0020] In some embodiments, the control represents PD-L1 levels in patients before administration of a GM-CSF antagonist.
[0021] In some embodiments, the control is the reference PD-L1 level in control patients receiving cancer treatment without using a GM-CSF antagonist, or the reference PD-L1 level based on historical data.
[0022] In some embodiments, the level of PD-L1 in the patient is reduced by at least 10% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 15% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 20% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 30% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 40% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 45% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 50% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 60% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 70% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 75% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 80% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 85% compared to the control. In some embodiments, the level of PD-L1 in the patient is reduced by at least 90% compared to the control.
[0023] In some embodiments, PD-L1 is expressed on MDSCs. In some embodiments, PD-L1 is expressed on circulating MDSCs. In some embodiments, PD-L1 is expressed on plasma-derived MDSCs. In some embodiments, PD-L1 is expressed on tumor cells. In some embodiments, PD-L1 is expressed on tumor-infiltrating immune cells.
[0024] In some embodiments, the patient has circulating myeloid-derived suppressor cells (MDSCs).
[0025] In some embodiments, the patient has cancer with low levels of infiltrating T cells.
[0026] In some embodiments, the patient has cancer refractory to immune checkpoint inhibitors (ICIs).
[0027] In some embodiments, the patient has advanced or metastatic cancer.
[0028] In some embodiments, the patient has cancer selected from non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, colon adenocarcinoma, rectal adenocarcinoma, endometrial cancer, adenocarcinoma, appendix adenocarcinoma, acute myeloid leukemia, breast cancer, or ovarian cancer.
[0029] In some embodiments, the patient has cancer selected from non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or pancreatic cancer.
[0030] In some embodiments, the patient has cancer selected from breast cancer, colorectal cancer (CRC), prostate cancer, melanoma, bladder cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, gastric cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma, non-Hodgkin lymphoma, cervical cancer, gastrointestinal cancer, genitourinary cancer, brain cancer, mesothelioma, renal cell carcinoma, gynecological cancer, ovarian cancer, endometrial cancer, lung cancer, gastrointestinal cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma, cholangiocarcinoma, brain cancer, mesothelioma, malignant melanoma, Merkel cell carcinoma, multiple myeloma, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome or acute lymphoblastic leukemia.
[0031] In some embodiments, the patient has cancer selected from stage IV breast cancer, stage IV colorectal cancer (CRC), prostate cancer, or melanoma.
[0032] The method according to any one of the prior claims, further comprising administering at least one other cancer therapy to the patient.
[0033] In some embodiments, at least one other cancer therapy is chemotherapy, MDSC-targeted therapy, immunotherapy, radiotherapy, or a combination thereof.
[0034] In some embodiments, GM-CSF antagonists and other cancer therapies are administered simultaneously.
[0035] In some embodiments, the GM-CSF antagonist and other cancer therapies are administered sequentially.
[0036] In some embodiments, the patient has received treatment with other cancer therapies prior to the administration of the GM-CSF antagonist.
[0037] In some embodiments, patients receive treatment with a GM-CSF antagonist before receiving other cancer therapies.
[0038] In some embodiments, the alternative cancer therapy is an ICI.
[0039] In some embodiments, ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, or A2aR.
[0040] In some embodiments, the ICI is selected from anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, or semiprimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, or durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
[0041] In some embodiments, ICI is an anti-PD-L1 antibody.
[0042] In some embodiments, the method further includes administering a chemotherapeutic agent to the patient.
[0043] In some embodiments, MDSC-targeted therapy is selected from anti-CFS-1R antibodies, anti-IL-6 antibodies, all-trans retinoic acid, axitinib, entinostat, gemcitabine, or phenformin, and combinations thereof.
[0044] In some embodiments, immunotherapy is selected from monoclonal antibodies, cytokines, cancer vaccines, T-cell engagement therapies, and combinations thereof.
[0045] In some embodiments, the monoclonal antibody is selected from anti-CD3 antibody, anti-CD52 antibody, anti-PD1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody, anti-CD20 antibody, anti-BCMA antibody, bispecific antibody, or bispecific T cell engager (BiTE) antibody, and combinations thereof.
[0046] In some embodiments, the cytokines are selected from IFNa, IFNp, IFNy, IFN, IL-2, IL-7, IL-15, IL-21, IL-11, IL-12, IL-18, hGM-CSF, TNFa, or any combination thereof.
[0047] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF antibody or a fragment thereof.
[0048] In some embodiments, the GM-CSF antagonist is a soluble GM-CSF receptor.
[0049] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0050] In some embodiments, the anti-GM-CSF receptor antibody or a fragment thereof is an anti-GM-CSFRα antibody or a fragment thereof.
[0051] In some embodiments, the anti-GM-CSFRα antibody or fragment thereof is a monoclonal antibody specific to human GM-CSFRα.
[0052] In some embodiments, the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0053] In some embodiments, the anti-GM-CSFRα antibody is mavrilimumab.
[0054] In some embodiments, the anti-GM-CSFRα antibody fragment comprises a light chain complementarity determination region 1 (LCDR1) defined by SEQ ID NO: 6, a light chain complementarity determination region 2 (LCDR2) defined by SEQ ID NO: 7, and a light chain complementarity determination region 3 (LCDR3) defined by SEQ ID NO: 8, as well as a heavy chain complementarity determination region 1 (HCDR1) defined by SEQ ID NO: 3, a heavy chain complementarity determination region 2 (HCDR2) defined by SEQ ID NO: 4, and a heavy chain complementarity determination region 3 (HCDR3) defined by SEQ ID NO: 5.
[0055] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in a reduction in MDSC levels in patients compared to controls.
[0056] In some embodiments, administration of a GM-CSF antagonist and / or ICI results in a reduction in the level of MDSC-mediated immunosuppressive activity in the patent compared to a control.
[0057] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in a decrease in the percentage of Lin-CD14+HLA-DR-M-MDSC in the peripheral blood of patients compared to controls.
[0058] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in an increase in the percentage of mature MDSC cells in patients compared to controls.
[0059] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in a decrease in the levels of Treg cells, macrophages, and / or neutrophils compared to controls.
[0060] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in a reduction in the levels of inhibitory cytokines.
[0061] In some embodiments, the inhibitory cytokine is selected from IL-10 and TGFβ.
[0062] In some embodiments, administration of GM-CSF antagonists and / or ICIs results in a reduction in immunosuppressive factor levels.
[0063] In some embodiments, the immunosuppressive factor is selected from arginase 1, inducible nitric oxide synthase (iNOS), peroxynitrite, nitric oxide, reactive oxygen species, tumor-associated macrophages, and combinations thereof.
[0064] In some embodiments, administration of a GM-CSF antagonist and / or ICI results in an increase in CD4+ T effector cell levels compared to a control.
[0065] In some embodiments, the control is a pre-treatment level or percentage in the patient, or a reference level or percentage based on historical data.
[0066] In some embodiments, the present invention provides a pharmaceutical composition for treating cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, comprising a GM-CSF antagonist and an ICI.
[0067] In some embodiments, the present invention provides a pharmaceutical composition for treating cancer, comprising a GM-CSF antagonist and an ICI.
[0068] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF antibody or a fragment thereof.
[0069] In some embodiments, the GM-CSF antagonist is a soluble GM-CSF receptor.
[0070] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0071] In some embodiments, the anti-GM-CSF receptor antibody or a fragment thereof is an anti-GM-CSFRα antibody or a fragment thereof.
[0072] In some embodiments, the anti-GM-CSFRα antibody or fragment thereof is a monoclonal antibody specific to human GM-CSFRα.
[0073] In some embodiments, the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0074] In some embodiments, the anti-GM-CSFRα antibody is maplilimumab.
[0075] In some embodiments, the anti-GM-CSFRα antibody fragment comprises a light chain complementarity determination region 1 (LCDR1) defined by SEQ ID NO: 6, a light chain complementarity determination region 2 (LCDR2) defined by SEQ ID NO: 7, and a light chain complementarity determination region 3 (LCDR3) defined by SEQ ID NO: 8, as well as a heavy chain complementarity determination region 1 (HCDR1) defined by SEQ ID NO: 3, a heavy chain complementarity determination region 2 (HCDR2) defined by SEQ ID NO: 4, and a heavy chain complementarity determination region 3 (HCDR3) defined by SEQ ID NO: 5.
[0076] In some embodiments, ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, and combinations thereof.
[0077] In some embodiments, the ICI is selected from anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, or semiprimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, or durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
[0078] In some embodiments, the present invention provides a kit for treating cancer having a KRAS mutation, comprising a pharmaceutical composition comprising a GM-CSF antagonist and a pharmaceutical composition comprising at least one other cancer therapy selected from chemotherapy, MDSC-targeted therapy, immunotherapy, radiotherapy, and combinations thereof.
[0079] In some embodiments, the present invention provides a kit for treating cancer, comprising a pharmaceutical composition comprising a GM-CSF antagonist and a pharmaceutical composition comprising at least one other cancer therapy selected from chemotherapy, MDSC-targeted therapy, immunotherapy, radiotherapy, and combinations thereof.
[0080] In some embodiments, the immunotherapy is an ICI selected from anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, or cemiprimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, or durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
[0081] In some embodiments, the present invention provides a method for treating cancer in which the activation of the KRAS signaling pathway is increased compared to normal, comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein the administration of the GM-CSF antagonist results in inhibition of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
[0082] In some embodiments, the present invention provides a method for inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in cancer patients with increased activation of the KRAS signaling pathway compared to normal, the method comprising administering a GM-CSF antagonist to the patient.
[0083] In some embodiments, the present invention provides a method for enhancing the immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the patient has cancer in which activation of the KRAS signaling pathway is increased compared to normal, and the immune response is increased compared to a control.
[0084] In one embodiment, the present invention provides a method for suppressing PD-L1 in cancer patients with increased activation of the KRAS signaling pathway compared to normal, the method comprising administering a GM-CSF antagonist to patients requiring treatment compared to a control.
[0085] In some embodiments, the present invention provides a pharmaceutical composition for treating cancer in which activation of the KRAS signaling pathway is increased compared to normal, comprising a GM-CSF antagonist and an ICI.
[0086] In some embodiments, the present invention provides a kit for treating cancer in which activation of the KRAS signaling pathway is increased compared to normal, comprising a pharmaceutical composition comprising a GM-CSF antagonist and a pharmaceutical composition comprising at least one other cancer therapy selected from chemotherapy, MDSC-targeted therapy, immunotherapy, radiotherapy, and combinations thereof.
[0087] In some embodiments, a normal level of KRAS signaling pathway activation is the level of KRAS signaling pathway activation in a healthy non-cancer patient or in a tissue sample obtained from a healthy non-cancer patient. In some embodiments, a normal level of KRAS signaling pathway activation is the level of KRAS signaling pathway activation in a non-KRAS-mutated cancer patient or in a tissue sample obtained from a non-KRAS-mutated cancer patient. In some embodiments, a normal level of KRAS signaling pathway activation is the level of KRAS signaling pathway activation in non-cancer tissue from a KRAS-mutated cancer patient. In some embodiments, a normal level of KRAS signaling pathway activation is the level of KRAS signaling pathway activation in non-cancer cells.
[0088] In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located in genes encoding proteins involved in the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located in the KRAS gene. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located in genes encoding proteins involved in signaling pathways upstream of the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located in genes encoding proteins involved in signaling pathways downstream of the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are oncogenic mutations.
[0089] In some embodiments, the present invention provides a method for enhancing the immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the patient has cancer in which activation of the NRAS signaling pathway is increased compared to normal, and the immune response is increased compared to a control.
[0090] In some embodiments, the present invention provides a method for enhancing an immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the patient has cancer having a perturbed JAK2 signaling pathway compared to normal, and the immune response is increased compared to a control.
[0091] In some embodiments, the present invention provides a method for enhancing an immune response for cancer treatment, comprising administering a GM-CSF antagonist to a patient undergoing cancer treatment, wherein the patient has cancer having a perturbed PTPN11 signaling pathway compared to normal, and the immune response is increased compared to a control.
[0092] In some embodiments, the present invention provides a method for treating cancer in a patient, comprising administering a therapeutically effective dose of a GM-CSF antagonist to the patient in need of treatment, wherein the administration improves, stabilizes, and reduces one or more symptoms of cancer compared to a control, and the cancer is chronic myelomonocytic leukemia (CMML) or juvenile myelomonocytic leukemia (JMML).
[0093] In some embodiments, the cancer has one or more mutations in KRAS, NRAS, PTPN11, or JAK2.
[0094] In some embodiments, CMML is classified as MPN-CMML. In some embodiments, CMML is classified as MDS-CMML.
[0095] In some embodiments, CMML is classified as CMML-0. In some embodiments, CMML is classified as CMML-1. In some embodiments, CMML is classified as CMML-2.
[0096] In some embodiments, administration of GM-CSF antagonists to patients with CMML shortens the time to progression to AML. In some embodiments, administration of GM-CSF antagonists to patients with CMML prevents progression to AML.
[0097] In some embodiments, administration of GM-CSF antagonists to patients with JMML shortens the time to progression to AML. In some embodiments, administration of GM-CSF antagonists to JMML patients prevents progression to AML.
[0098] In some embodiments, the GM-CSF antagonist is selected from the group consisting of maprilimumab, namilumab, ocilimab, rengilumab, gymcirumab, and TJM2. In some embodiments, the GM-CSF antagonist is maprilimumab. In some embodiments, the GM-CSF antagonist is namilumab. In some embodiments, the GM-CSF antagonist is ocilimab. In some embodiments, the GM-CSF antagonist is rengilumab. In some embodiments, the GM-CSF antagonist is gymcirumab. In some embodiments, the GM-CSF antagonist is TJM2.
[0099] The drawings are for illustrative purposes only and not for limitation. [Brief explanation of the drawing]
[0100] [Figure 1] This is an exemplary bar graph illustrating a T cell proliferation assay using CD14+ cells (MDSCs) from the blood of patients with pancreatic cancer. T cell proliferation is suppressed after co-culturing healthy donor allogeneic T cells with CD14+ cells selected from the blood of pancreatic cancer patients, compared to T cells cultured in complete medium alone. T cell proliferation is rescued after culturing with anti-GM-CSFRα antibody and CD14+ cells selected from the blood of pancreatic cancer patients. [Figure 2] This is an exemplary graph (n=2) showing GM-CSF expression levels in different cancer cell lines, measured by the amount of human GM-CSF secreted into the cancer cell supernatant. The plot represents the mean of two independent ELISA readings performed in two consecutive sequences, and the error bars indicate the standard deviation (+ / -). [Figure 3]This is a series of exemplary bar graphs illustrating that a tumor cell condition medium can polarize monocytes into phenotypic MDSCs (CD14+ cells). Four different cell lines were seeded and cultured according to methods known in the art to generate tumor condition medium (CM). CD14+ monocytes were then cultured in the presence of CM for 6 days, and gene and protein expression were analyzed. Low levels of HLA-DR biomarkers indicate the MDSC phenotype. When CD14+ monocytes were incubated in condition medium from GM-CSF-expressing cancer cells, an increase in phenotypic MDSCs was observed compared to CD+14 cells grown in normal culture medium (control). [Figure 4] This is a series of exemplary bar graphs showing PD-L1 expression on MDSCs cultured in various media. The data indicate that cancer cell condition medium (CM) and CM supplemented with recombinant GM-CSF can induce PD-L1 expression on MDSCs. Additionally, anti-GM-CSFRα antibodies (Ab) can reduce PD-L1 expression levels on MDSCs. [Figure 5A] This is a series of exemplary bar graphs showing PD-L1 expression on MDSCs cultured in various media. The data show that cancer cell condition medium (CM) and CM supplemented with recombinant GM-CSF on day 1 can induce PD-L1 expression on MDSCs compared to MDSCs grown in normal culture medium. Furthermore, anti-GM-CSFRα antibody (Ab) can reduce the level of PD-L1 expression on MDSCs grown in CM. The data in Figure 5A shows PD-L1 expression when CM and anti-GM-CSFRα antibody (Ab) are added simultaneously. PD-L1 expression was measured after 3 days of treatment. Figure 5B shows PD-L1 expression when anti-GM-CSFRα antibody is added 72 hours after culturing with CM. PD-L1 expression was measured 24 hours after treatment with anti-GM-CSFRα antibody. [Figure 5B]This is a series of exemplary bar graphs showing PD-L1 expression on MDSCs cultured in various media. The data show that cancer cell condition medium (CM) and CM supplemented with recombinant GM-CSF on day 1 can induce PD-L1 expression on MDSCs compared to MDSCs grown in normal culture medium. Furthermore, anti-GM-CSFRα antibody (Ab) can reduce the level of PD-L1 expression on MDSCs grown in CM. The data in Figure 5A shows PD-L1 expression when CM and anti-GM-CSFRα antibody (Ab) are added simultaneously. PD-L1 expression was measured after 3 days of treatment. Figure 5B shows PD-L1 expression when anti-GM-CSFRα antibody is added 72 hours after culturing with CM. PD-L1 expression was measured 24 hours after treatment with anti-GM-CSFRα antibody. [Figure 6A] A series of exemplary bar graphs showing the proliferation of CD8+ T cells cultured for 3 days with or without cancer cell-conditioning medium (+ / - 100 μg / mL anti-GM-CSFRα antibody) from healthy control (n=3). CD3+ T cells were labeled with CFSE on day 3, stimulated with CD3 / CD28 / IL-2, and co-cultured with monocytes for 5 days. Proliferation was monitored by measuring CFSE dilution and normalized to the proliferation of T cells co-cultured with monocytes in the corresponding cell culture medium. [Figure 6B]This is a series of exemplary bar graphs showing T cell proliferation by monocytes treated with conditional media from GM-CSF-expressing cancer cell lines, with or without supplementation with human recombinant GM-CSF and / or anti-GM-CSFRα antibody (Ab). Monocytes were cultured for 3 days in conditional media (CM) from GM-CSF-expressing cancer cell lines. T cells (1 × 10⁵ cells) were prepared by labeling with 0.1 μM CFSE and stimulating them with 10 ng / mL IL-2 and 10 μL soluble CD3 / CD28 T cell activator (ImmunoCult) in IMDM cell culture medium. The stimulated T cells were then co-cultured in a mixed lymphocyte reaction (MLR) with CM-treated monocytes (in a 2:1 monocyte:T cell ratio), with or without recombinant GM-CSF (10 ng / mL) and / or anti-GM-CSFRα antibody (100 μg / mL). T cells stimulated in IMDM culture medium along with healthy monocytes were used as a control. T cells were grown for 5 days, collected, and stained for CD4 and CD8, markers for helper T and cytotoxic T cells, respectively. Cell proliferation was measured by flow cytometry and evaluated by CFSE dilution. The left panel shows the results of the T cell proliferation assay as a percentage of proliferating cells, and the right panel shows the results as maximum (MFI)% by flow cytometry (signal detection of CFSE dilution in CD4+ or CD8+ cells). [Figure 6C] This is an exemplary graph of the proliferation of CD8+ T cells cultured for 3 days with and without colorectal cancer cell conditional medium, with and without the conditional medium. Anti-GM-CSFRα antibody was added to the monocyte culture on day 0, and anti-PD-L1 antibody was added to the MLR on day 3. CD3+ T cells were labeled with CFSE, stimulated with CD3 / CD28 / IL-2, and co-cultured with monocytes for 5 days. Proliferation was monitored by measuring CFSE dilution and normalized to the proliferation of T cells co-cultured with monocytes in the corresponding cell culture medium. [Figure 7A]This is an exemplary workflow for a study investigating the polarization of CD14+ monocytes to phenotypic MDSCs using KRAS-mutated cancer cell conditional medium. CD14= monocytes were incubated for 3 days with either basic medium or a conditional medium derived from cancer cells, followed by phenotypic analysis by flow cytometry. [Figure 7B] These are a series of representative histogram overlays showing degreased HLA=DR expression and increased CD11b and PD-L1 expression. [Figure 7C] These are a series of exemplary bar graphs showing the relative expression of HLA-DR, CD11b, and PD-L1 plotted as geometric mean fluorescence intensity (gMFI) in healthy donor monocytes cultured in cancer cell condition medium. P values were generated using a two-sided pairwise comparison Student's test. [Figure 8A] Figure 8A is a representative bar graph showing PD-L1 expression on MDSCs cultured with various media and anti-GM-CSFRα antibodies. Figure 8A is a representative graph showing the relative expression of PD-L1, plotted as geometric mean fluorescence intensity (gMFI), in healthy donor monocytes cultured in conditional media from colorectal cancer cells and pancreatic cancer cells, with or without anti-GM-CSFRα antibodies at various concentrations. Figure 8B is a representative graph showing the relative expression of PD-L1, plotted as geometric mean fluorescence intensity (gMFI), in healthy donor monocytes cultured in conditional media from cervical cancer cells. P-values were generated using standard one-way ANOVA with Dunnett's mean multiple comparisons. (CM = conditional media, ns = not significant) [Figure 8B]Figure 8A is a representative bar graph showing PD-L1 expression on MDSCs cultured with various media and anti-GM-CSFRα antibodies. Figure 8A is a representative graph showing the relative expression of PD-L1, plotted as geometric mean fluorescence intensity (gMFI), in healthy donor monocytes cultured in conditional media from colorectal cancer cells and pancreatic cancer cells, with or without anti-GM-CSFRα antibodies at various concentrations. Figure 8B is a representative graph showing the relative expression of PD-L1, plotted as geometric mean fluorescence intensity (gMFI), in healthy donor monocytes cultured in conditional media from cervical cancer cells. P-values were generated using standard one-way ANOVA with Dunnett's mean multiple comparisons. (CM = conditional media, ns = not significant) [Figure 9A] These are a series of illustrative graphs showing the average tumor volume in mice with pancreatic cancer. Figure 9A is a representative graph showing the average tumor volume of mice in each treatment group 3 days after the end of treatment. Figure 9B is a representative graph showing the average tumor volume of mice in each treatment group 12 days after the end of treatment. [Figure 9B] These are a series of illustrative graphs showing the average tumor volume in mice with pancreatic cancer. Figure 9A is a representative graph showing the average tumor volume of mice in each treatment group 3 days after the end of treatment. Figure 9B is a representative graph showing the average tumor volume of mice in each treatment group 12 days after the end of treatment. [Figure 10] This is an exemplary Kaplan-Meier plot of time to reach a tumor volume of 2000 mm³ compared to the log-rank test. Mice treated with a GM-CSF antagonist alone or in combination with an anti-PD-1 antibody had a longer time to reach a tumor volume of 2000 mm³ compared to the control group. [Modes for carrying out the invention]
[0101] definition To facilitate understanding of the present invention, certain terms are first defined below. Additional definitions of the following terms and other terms are established throughout this specification. Published documents and other reference materials referenced herein to provide context for the present invention and to offer additional details relating to its implementation are incorporated herein by reference.
[0102] Antibody: As used herein, the term “antibody” refers to an immunoglobulin molecule and an immunoglobulin (Ig) molecule that contains an immunoactive portion, i.e., an antigen-binding site that binds to an antigen (responds to an immune reaction). By “binding” or “responds to an immune reaction,” it means that the antibody reacts with one or more desired antigenic determinants. Antibodies include antibody fragments. Antibodies also include, but are not limited to, polyclonal, monoclonal, chimeric dAb (domain antibodies), single-chain, Fab, Fab', F(ab')2 fragments, scFv, and Fab expression libraries. Antibodies may be whole antibodies, immunoglobulins, or antibody fragments.
[0103] Amino Acids: As used herein, the term “amino acid” means, in its broadest sense, any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N-C(H)(R)-COOH. In some embodiments, an amino acid is a naturally occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid, in some embodiments, an amino acid is a d-amino acid, and in some embodiments, an amino acid is an l-amino acid. “Standard amino acid” means any of the 20 standard l-amino acids commonly found in naturally occurring peptides. “Non-standard amino acid” means any amino acid other than a standard amino acid, whether synthetically prepared or obtained from a natural source. As used herein, “synthetic amino acid” includes, but is not limited to, salts, amino acid derivatives (such as amides), and / or substitutions of chemically modified amino acids. Amino acids, including carboxyl-terminal amino acids and / or amino-terminal amino acids in peptides, may be modified by methylation, amidation, acetylation, protecting groups, and / or substitution with other chemical groups that can alter the cyclic half-life of the peptide without adversely affecting their activity. Amino acids can be involved in disulfide bonds. Amino acids may have one or more post-translational modifications, such as association with one or more chemical substances (e.g., methyl group, acetate group, acetyl group, phosphate group, formyl moiety, isoprenoid group, sulfate group, polyethylene glycol moiety, lipid moiety, carbohydrate moiety, biotin moiety, etc.). The term “amino acid” is used interchangeably with “amino acid residue” and may refer to free amino acids and / or amino acid residues of peptides. Whether the term refers to a free amino acid or a peptide residue should be clear from the context in which the term is used.
[0104] Improvement: As used herein, the term "improvement" means the prevention, reduction, or mitigation of a condition, or an improvement in the condition of the subject. Improvement includes, but does not require, complete recovery from or complete prevention of a disease condition. In some embodiments, improvement includes an increased level of the relevant protein or its activity that is deficient in the relevant disease tissue.
[0105] Approximately or about: As used herein, the terms “approximately” or “about” applied to one or more values of interest refer to values that are similar to the given reference value. In certain embodiments, unless otherwise specified or evident from the context, the terms “approximately” or “about” refer to a range of values that fall within the range of 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) the given reference value (except where such a number exceeds 100% of the possible value).
[0106] Delivery: As used herein, the term “delivery” encompasses both local delivery and systemic delivery.
[0107] To improve, increase, inhibit, or reduce: As used herein, the terms “improve,” “increase,” “inhibit,” or “reduce,” or their grammatical equivalents, refer to values relative to baseline measurements, such as measurements in the same individual before the initiation of the treatment described herein, or in a control subject (or control subjects) not receiving the treatment described herein, for example, measurements in a subject given a placebo. A “control” or “control subject” is a subject suffering from the same form of the disease as the subject being treated and being approximately the same age as the subject being treated.
[0108] "Inhibition" or "Inhibition": As used herein, "inhibition" or "inhibition," or its grammatical equivalent, means reduction, decrease, or inhibition of biological activity. Neutralization: As used herein, neutralization means reduction or inhibition of the biological activity of the protein to which the neutralizing antibody binds, in this case GM-CSFRα, for example, reduction or inhibition of GM-CSF binding to GM-CSFRα, or reduction or inhibition of signaling by GM-CSFRα, as measured, for example, by a GM-CSFRα-mediated response. The reduction or inhibition of biological activity may be partial or total. The degree to which an antibody neutralizes GM-CSFRα is referred to as its neutralizing potency.
[0109] "KRAS mutation": As used herein, "KRAS mutation," "KRAS variant," "K-Ras mutation," "K-Ras variant," or grammatical equivalent means one or more mutations in the KRAS gene or protein compared to the wild-type sequence. The wild-type or normal KRAS gene inhibits tumor growth, while the mutant KRAS gene promotes cell growth and causes tumorigenesis. "Cancer with a KRAS mutation" or "KRAS mutant cancer" is cancer or tumor cell having an abnormal level of KRAS expression, including but not limited to (a) cancer cells or tumor cells containing somatic KRAS mutations, or (b) amplification of the KRAS-coding DNA or overexpression of the KRAS gene compared to levels found in normal non-cancer cells. As used herein, "cancer with increased activation of the KRAS signaling pathway" is cancer or tumor cell having one or more mutations in a gene that result in abnormal activation of the KRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased activation of the KRAS signaling pathway are located in a gene that codes for a protein involved in the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located within the KRAS gene. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located within a gene encoding a protein involved in an upstream signaling pathway of the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are located within a gene encoding a protein involved in a downstream signaling pathway of the KRAS signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the KRAS signaling pathway are oncogenic mutations.
[0110] Patient: As used herein, the term “patient” refers to any organism to which the provided composition may be administered, for example, for experimental, diagnostic, preventive, cosmetic, and / or therapeutic purposes. Typical patients include animals (mammals, such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is human. Humans include prenatal and postnatal forms.
[0111] Pharmacopoeia-acceptable: As used herein, the term “pharmacopoeia-acceptable” means a substance that, within the bounds of appropriate medical judgment, is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response, or other problems or complications, and that is commensurate with a reasonable benefit / risk ratio.
[0112] Substantial Identity: In this specification, the term “substantial identity” is used to refer to a comparison between amino acid sequences or nucleic acid sequences. As will be understood by those skilled in the art, two sequences are generally considered “substantial identity” if they contain identical residues at corresponding positions. As is well known in the art, amino acid sequences or nucleic acid sequences can be compared using any of a variety of algorithms, including BLAS TN for nucleotide sequences and BLASTP, Gap BLAST, and PSI-BLAST, which are available in commercially available computer programs, for amino acid sequences. Examples of such programs are described in Altschul, et al., Basic local alignment search tool, J Mal. Biol., 215(3):403-410, 1990; Altschul, et al., Methods in Enzymology; Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener, et al., (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132), Humana Press, 1999. In addition to identifying identical sequences, the programs described above typically provide a numerical value indicating the degree of identity. In some embodiments, two sequences are considered substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more of the corresponding residues are identical across the relevant sequence of residues. In some embodiments, the relevant sequence is the complete sequence.In some embodiments, the relevant sequence is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.
[0113] Subject: As used herein, the term “subject” means a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, pig, sheep, horse, or primate). Human includes prenatal and postnatal forms. In many embodiments, the subject is a human. The subject may also be a patient, meaning a human being presented to a healthcare provider for the diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” The subject may be suffering from or susceptible to a disease or disorder, and may or may not exhibit symptoms of the disease or disorder.
[0114] Substantially: As used herein, the term “substantially” refers to a qualitative state that exhibits all or nearly all range or degree of the desired features or characteristics. Those skilled in the biological art will understand that biological and chemical phenomena rarely, if ever, reach completion and / or progress to completeness, or achieve complete results, or attain or avoid absolute results. Therefore, the term “substantially” is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0115] Whole-body distribution or delivery: As used herein, the terms “whole-body distribution,” “whole-body delivery,” or their grammatical equivalents refer to a delivery or distribution mechanism or approach that affects the entire body or organism. Typically, whole-body distribution or delivery is achieved through the body’s circulatory system, e.g., blood flow. Compare this to the definition of “local distribution or delivery.”
[0116] Therapeutic dose: As used herein, the term “therapeutic dose” of a therapeutic agent means an amount sufficient to treat, diagnose, prevent, and / or delay the onset of symptoms of a disease, disorder, and / or condition when administered to a subject suffering from or susceptible to the disease, disorder, and / or condition. It will be understood by those skilled in the art that a therapeutic dose is typically administered via a dosing regimen comprising at least one unit dose.
[0117] Treatment: As used herein, the terms “to treat,” “treatment,” or “to treat” mean any method used to partially or completely reduce, improve, alleviate, inhibit, prevent, delay the onset, reduce the severity, and / or reduce the incidence of one or more symptoms or characteristics of a particular disease, disorder, and / or condition. Treatment may be administered to subjects who do not show signs of the disease and / or only show early signs of the disease, for the purpose of reducing the risk of developing a disease-related condition.
[0118] The present invention provides, in particular, a method for treating cancer in patients requiring treatment, using a GM-CSF antagonist. In certain embodiments, the present invention provides a method for treating cancer by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in patients requiring treatment, using a GM-CSF antagonist. In some embodiments, the GM-CSF antagonist is used in combination with an immune checkpoint inhibitor. The present invention is intended to be particularly effective in treating cancers that are refractory or resistant to immune checkpoint inhibitors (ICIs), or cancers that are terminal or metastatic.
[0119] Various aspects of the present invention are described in detail in the following sections. The use of these sections is not intended to limit the present invention. Each section may be applied to any aspect of the present invention. In this application, the use of "or" means "and / or" unless otherwise specified.
[0120] KRAS (Kirsten rat sarcoma virus oncogene homolog) mutation The KRAS (Kirsten rat sarcoma virus oncogene homolog) gene provides instructions for producing a protein called K-Ras, which is part of a signaling pathway known as the RAS / MAPK pathway. This protein relays signals from the outside of the cell to the cell nucleus. These signals instruct the cell to grow, divide (proliferate), mature, or perform specialized functions (differentiation). The K-Ras protein is a GTPase, which means it converts a molecule called GTP into another molecule called GDP. In this way, the K-Ras protein acts like a switch that is turned on and off by the GTP and GDP molecules. To transmit signals, it needs to be turned on by attaching to (binding to) a GTP molecule. The K-Ras protein is turned off (inactivated) when GTP is converted to GDP. When the protein is bound to GDP, the signal is not relayed to the cell nucleus.
[0121] The KRAS gene belongs to a class of genes known as oncogenes. Oncogenes are normal genes that play a crucial role in stimulating regulated cell proliferation. Mutations in these genes lead to uncontrolled proliferation and the development of cancer. The RAS gene is expressed in normal cells and is involved in regulated cell proliferation. Three distinct mutations of RAS have been identified: H-ras, N-ras, and K-ras. Generally, colon, pancreatic, and lung cancers have KRAS mutations, bladder tumors have HRAS mutations, and hematopoietic neoplasms are associated with NRAS mutations.
[0122] KRAS mutations may be associated with malignancies such as lung adenocarcinoma, myxoid adenoma, pancreatic ductal carcinoma, and colorectal cancer. In human colorectal cancer, KRAS mutations appear to induce GST-π overexpression via AP-1 activation. See, for example, Miyanishi et al., Gastroenterology, 2001;121(4):865-74.
[0123] Mutant KRAS mutations have been found in colon cancer (Burmer GC, Loeb LA, 1989, Proc. Natl. Acad. Sci. USA, 86(7):2403-2407), pancreatic cancer (Almoguera C, et al., 1988, Cell, 53(4):549-554), and lung cancer (Tam IY, et al., 2006, Clin. Cancer Res., 12(5):1647-1653). KRAS accounts for 90% of RAS mutations in lung adenocarcinoma (Forbes S, et al. Cosmic 2005. Br J Cancer, 2006;94:318-322).
[0124] The KRAS gene can also be amplified in colorectal cancer. KRAS amplification may be mutually exclusive with KRAS mutations. See, for example, Valtorta E, et al., 2013, Int. J. Cancer, 133(5):1259-65. Amplification of wild-type KRAS has also been observed in ovarian cancer, gastric cancer, uterine cancer, and lung cancer. See, for example, Chen Y, et al., 2014, PLoS ONE, 9(5):e98293.
[0125] The human KRAS gene sequence has two preferred transcription variants and has the nucleic acid sequences indicated by GenBank accession numbers NM_033360 (transcription variant a) (SEQ ID NO: 9) and NM_004985.5 (transcription variant b) (SEQ ID NO: 10). The human KRAS protein sequence has two preferred variants and has the amino acid sequences indicated by GenBank accession numbers NP_203524 (isoform a) (SEQ ID NO: 11) and NP_004976.2 (isoform b) (SEQ ID NO: 12).
[0126] In some embodiments, cancer having a KRAS mutation is cancer cells or tumor cells containing oncogenic KRAS mutations. Cancer-related oncogenic KRAS mutations include, but are not limited to, G12A, G12S, G12D, G12V, G13D, G12C, Q61R, Q61L, Q61K, G12R, and G12C. In some embodiments, the KRAS mutation includes oncogenic substitutions of G12 and / or G13 that result in constitutive activation of KRAS. Those skilled in the art will understand that KRAS mutations other than those identified above, and / or combinations of the above KRAS mutations, and / or other KRAS mutations that preferably result in constitutive activation of KRAS, are also oncogenic KRAS mutations encompassed by the present invention. In some embodiments, cancer having a KRAS mutation is cancer cells or tumor cells containing somatic KRAS mutations. In some embodiments, cancer having a KRAS mutation is a cancer cell or tumor cell having constitutive activation of the KRAS signaling pathway, which includes, but is not limited to, amplification of the KRAS-encoding DNA compared to levels found in normal non-cancer cells, or overexpression of the KRAS gene.
[0127] In one embodiment, the present invention provides a method for treating cancer with increased KRAS signaling pathway activation, particularly using a GM-CSF antagonist. As used herein, “cancer with increased KRAS signaling pathway activation” is cancer or tumor cells having one or more mutations in a gene resulting in abnormal activation of the KRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased KRAS signaling pathway activation are located in a gene encoding a protein involved in the KRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased KRAS signaling pathway activation are located in the KRAS gene. In some embodiments, the one or more mutations resulting in increased KRAS signaling pathway activation are located in a gene encoding a protein involved in an upstream signaling pathway of the KRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased KRAS signaling pathway activation are located in a gene encoding a protein involved in a downstream signaling pathway of the KRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased KRAS signaling pathway activation compared to normal are oncogenic mutations.
[0128] In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the RAF signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the MAPK signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the PI3K signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the AKT signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the RAL signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the Wnt signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the receptor tyrosine kinase (RTK) signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the mTOR signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the MEK signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the ERK signaling pathway. In some embodiments, one or a mutation resulting in increased activation of the KRAS signaling pathway compared to normal is located in a gene encoding a protein involved in the NF-κB signaling pathway.
[0129] In some embodiments, a KRAS mutation is one or more mutations in the KRAS gene or KRAS protein that promote cell proliferation, induce tumorigenesis, or result in amplification of the KRAS-coding DNA, or overexpression of the KRAS gene, deletion, abnormal overexpression, or activation of the KRAS protein compared to levels found in normal non-cancer cells. In some embodiments, one or more mutations include deletions, insertions, or substitutions of one or more nucleotides or amino acids in the gene or protein compared to the wild-type gene or protein. In some embodiments, a KRAS mutation is an amino acid substitution at residue G12 of the KRAS protein. In some embodiments, a KRAS mutation is an amino acid substitution at residue G13 of the KRAS protein. In some embodiments, a KRAS mutation includes oncogenic substitutions of G12 and / or G13 that result in constitutive activation of KRAS. In some embodiments, a KRAS mutation is an amino acid substitution at residue Q61 of the KRAS protein. In some embodiments, a KRAS mutation is a G12D mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12V mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G13D mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12C mutation of the KRAS protein. In some embodiments, the KRAS mutation is the Q61R mutation of the KRAS protein. In some embodiments, the KRAS mutation is the Q61L mutation of the KRAS protein. In some embodiments, the KRAS mutation is the Q61K mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12R mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12C mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12A mutation of the KRAS protein. In some embodiments, the KRAS mutation is the G12S mutation of the KRAS protein.
[0130] In some embodiments, cancers with KRAS mutations have elevated GM-CSF levels compared to controls. In some embodiments, elevated GM-CSF levels are detected in patient samples. In some embodiments, the patient sample is a serum sample. In some embodiments, the patient sample is a tissue sample. In some embodiments, the patient sample is derived from a tumor biopsy. In some embodiments, the control is the GM-CSF level in a healthy subject without cancer. In some embodiments, the control is the GM-CSF level in a healthy tissue sample from a patient. In some embodiments, patients are selected based on their baseline GM-CSF levels. In some embodiments, patients have elevated GM-CSF levels compared to controls.
[0131] NRAS (neuroblastoma RAS virus oncogene homolog) mutation NRAS proteins activate the Ras / Raf / MEK / ERK pathway in cells. This pathway lies downstream of the EGFR receptor and plays a central role in regulating various cellular functions that depend on the cellular environment, including cell proliferation, differentiation, survival, immortalization, invasion, and angiogenesis (as outlined in Peyssonnaux and Eychene, Biology of the Cell, 2001, 93:3-62). In fact, the Ras-dependent Raf-MEK-MAPK cascade is one of the important signaling pathways that transmits both pro-mitotic and infiltration signals from the cell surface to the nucleus, leading to changes in gene expression and cell fate.
[0132] In some embodiments, cancer having an NRAS mutation is cancer cells or tumor cells containing an oncogenic NRAS mutation. Cancer-related oncogenic NRAS mutations include, but are not limited to, G12A, G12S, G12D, G12V, G13D, G12C, E63R, E63L, E63K, G12R, and G12C. In some embodiments, the NRAS mutation includes oncogenic substitutions of G12 and / or E63 that result in constitutive activation of NRAS. Those skilled in the art will understand that NRAS mutations other than those identified above, and / or combinations of the above NRAS mutations, and / or other NRAS mutations that preferably result in constitutive activation of NRAS, are also oncogenic NRAS mutations encompassed by the present invention. In some embodiments, cancer having an NRAS mutation is cancer cells or tumor cells containing a somatic NRAS mutation. In some embodiments, cancer having an NRAS mutation is a cancer cell or tumor cell having constitutive activation of the NRAS signaling pathway, which includes, but is not limited to, amplification of the NRAS-encoding DNA or overexpression of the NRAS gene compared to levels found in normal non-cancer cells.
[0133] In one embodiment, the present invention provides a method for treating cancer with increased NRAS signaling pathway activation, particularly using a GM-CSF antagonist. As used herein, “cancer with increased NRAS signaling pathway activation” refers to cancer or tumor cells having one or more mutations in a gene that result in abnormal activation of the NRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased NRAS signaling pathway activation are located in a gene encoding a protein involved in the NRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased NRAS signaling pathway activation are located in the NRAS gene. In some embodiments, the one or more mutations resulting in increased NRAS signaling pathway activation are located in a gene encoding a protein involved in an upstream signaling pathway of the NRAS signaling pathway. In some embodiments, the one or more mutations resulting in increased NRAS signaling pathway activation compared to normal are oncogenic mutations.
[0134] In some embodiments, an NRAS mutation is one or more mutations in the KRAS gene or NRAS protein that promote cell proliferation, induce tumorigenesis, or result in amplification of the NRAS-coding DNA, or overexpression of the NRAS gene, deletion, abnormal overexpression, or activation of the NRAS protein compared to levels found in normal non-cancer cells. In some embodiments, one or more mutations include deletions, insertions, or substitutions of one or more nucleotides or amino acids in the gene or protein compared to the wild-type gene or protein. In some embodiments, an NRAS mutation is an amino acid substitution at residue G12 of the NRAS protein. In some embodiments, a KRAS mutation is an amino acid substitution at residue E63 of the NRAS protein. In some embodiments, an NRAS mutation includes oncogenic substitutions of G12 and / or E63 that result in constitutive activation of NRAS. In some embodiments, an NRAS mutation is an amino acid substitution at residue G12 of the NRAS protein. In some embodiments, an NRAS mutation is a G12D mutation of the NRAS protein. In some embodiments, an NRAS mutation is a G12V mutation of the NRAS protein. In some embodiments, the NRAS mutation is a G13D mutation in the KRAS protein. In some embodiments, the NRAS mutation is a G12C mutation in the NRAS protein. In some embodiments, the NRAS mutation is an E63R mutation in the NRAS protein. In some embodiments, the NRAS mutation is an E63L mutation in the NRAS protein. In some embodiments, the NRAS mutation is an E63K mutation in the NRAS protein. In some embodiments, the NRAS mutation is a G12R mutation in the NRAS protein. In some embodiments, the NRAS mutation is a G12C mutation in the NRAS protein. In some embodiments, the NRAS mutation is a G12A mutation in the NRAS protein. In some embodiments, the NRAS mutation is a G12S mutation in the NRAS protein.
[0135] In some embodiments, cancers with NRAS mutations have elevated GM-CSF levels compared to controls. In some embodiments, elevated GM-CSF levels are detected in patient samples. In some embodiments, the patient sample is a serum sample. In some embodiments, the patient sample is a tissue sample. In some embodiments, the patient sample is derived from a tumor biopsy. In some embodiments, the control is the GM-CSF level in a healthy subject without cancer. In some embodiments, the control is the GM-CSF level in a healthy tissue sample from a patient. In some embodiments, patients are selected based on their baseline GM-CSF levels. In some embodiments, patients have elevated GM-CSF levels compared to controls.
[0136] JAK2 (Janus kinase 2) and PTPN11 mutations The JAK2 gene is a member of the Janus kinase family and encodes Janus kinase 2, a non-receptor tyrosine kinase involved in signaling by members of the type II cytokine receptor family (e.g., interferon receptor), GM-CSF receptor family (IL-3R, IL-5R, and GM-CSF-R), gp130 receptor family (e.g., IL-6R), and single-chain receptors (e.g., Epo-R, Tpo-R, GH-R, PRL-R). JAK2 signaling is activated downstream of the prolactin receptor. Other names for JAK2 are JTK10 and THCYT3. SHP2, a non-receptor tyrosine phosphatase encoded by PTPN11, is also involved in signaling events downstream of growth factor, cytokine, hormone, antigen, and extracellular matrix receptors. JAK2 and SHP2 form a complex signaling network in hematopoietic progenitor cells. Perturbations of JAK2 and SHP2 signaling may induce hematopoietic malignancies.
[0137] JAK2 mutations are found in the majority of patients with myeloproliferative neoplasms (MPNs), which are clonal disorders of hematopoietic stem cells accompanied by increased proliferation and effective maturation of bone marrow cells, resulting in peripheral blood leukocytosis and excess red blood cells or platelets, highlighting the importance of constitutive activation of JAK2 signaling caused by mutations. Over 50% of MPN patients have the JAK2 V617F mutation. Furthermore, mutations in PTPN11, a gene encoding a cytoplasmic protein containing the tyrosine phosphatase SHP-2, are a major molecular event in JMML. SHP-2 is a signal transducer that relays signals from activated growth factor and cytokine receptors to RAS and other intracellular signaling molecules, and is required for sustained activation of the MAPK cascade. Accumulated evidence supports the idea that PTPN11, NRAS, and KRAS2 mutations are largely mutually exclusive in JMML and other hematological malignancies. On the other hand, PTPN11 deficiency was observed in only about 1.3% of CMML cases, indicating that PTPN11 lesions are a rare genetic event in CMML. Exons 3, 8, and 13 of PTPN11 are known mutation hotspots, resulting in mutant SHP2 proteins. SHP2 mutations detected in JMML patients are G60R, D61Y, D61N, E69K, A72T, A72V, T73I, E76K, E76Q, E76G, E139D, and G506P.
[0138] In one embodiment, the present invention provides a method for treating cancer with increased activation or perturbation of the JAK2 signaling pathway, particularly using a GM-CSF antagonist. As used herein, “cancer with increased activation or perturbation of the JAK2 signaling pathway” is cancer or tumor cells having one or more mutations in a gene resulting in abnormal activation of the JAK2 signaling pathway or perturbation of a downstream event (e.g., SHP2 signaling). In some embodiments, the one or more mutations resulting in increased activation of the JAK2 signaling pathway are located in a gene encoding a protein involved in the JAK2 signaling pathway. In some embodiments, the one or more mutations resulting in perturbation of the JAK2 signaling pathway are located in a gene encoding a protein involved in the JAK2 or SHP2 signaling pathway. In some embodiments, the one or more mutations resulting in increased activation of the JAK2 signaling pathway are located in the JAK2 gene. In some embodiments, the one or more mutations resulting in perturbation of the JAK2 signaling pathway are located in the JAK2 gene. In some embodiments, the one or more mutations resulting in perturbation of the JAK2 signaling pathway are located in the PTPN11 gene. In some embodiments, one or more mutations resulting in increased activation of the JAK2 signaling pathway are located in genes encoding proteins involved in the upstream signaling pathway of the JAK2 signaling pathway. In some embodiments, one or more mutations resulting in increased activation of the JAK2 signaling pathway are located in genes encoding proteins involved in the downstream signaling pathway of the JAK2 signaling pathway. In some embodiments, the gene encoding the protein involved in the downstream signaling pathway of the JAK2 signaling pathway is PTPN11. In some embodiments, one or more mutations resulting in increased activation of the JAK2 signaling pathway compared to normal are oncogenic mutations.
[0139] In some embodiments, a JAK2 mutation is one or more mutations in the JAK2 gene or JAK2 protein that disrupt the JAK / STAT pathway. In some embodiments, one or more mutations include one or more nucleotide or amino acid deletions, insertions, or substitutions in the gene or protein compared to the wild-type gene or protein. In some embodiments, a JAK2 mutation is an amino acid substitution at residue V617 of the JAK2 protein. In some embodiments, a JAK2 mutation is a V617F mutation in the JAK2 protein.
[0140] In some embodiments, cancers with JAK2 mutations have elevated GM-CSF levels compared to controls. In some embodiments, elevated GM-CSF levels are detected in patient samples. In some embodiments, the patient sample is a serum sample. In some embodiments, the patient sample is a tissue sample. In some embodiments, the patient sample is derived from a tumor biopsy. In some embodiments, the control is the GM-CSF level in a healthy subject without cancer. In some embodiments, the control is the GM-CSF level in a healthy tissue sample from a patient. In some embodiments, patients are selected based on their baseline GM-CSF levels. In some embodiments, patients have elevated GM-CSF levels compared to controls.
[0141] In some embodiments, an SHP2 mutation is one or more mutations in the PTPN11 gene or SHP2 protein, which disrupts downstream events of the JAK / STAT pathway. In some embodiments, one or more mutations involve the deletion, insertion, or substitution of one or more nucleotides or amino acids in the gene or protein compared to the wild-type gene or protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue G60 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue D61 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue E69 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue A72 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue T73 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue E76 of the SHP2 protein. In some embodiments, an SHP2 mutation is an amino acid substitution at residue E139 of the SHP2 protein. In some embodiments, the SHP2 mutation is an amino acid substitution at residue G506 of the SHP2 protein. In some embodiments, the SHP mutation is the G60R mutation of the SHP2 protein. In some embodiments, the SHP mutation is the G60R mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the G60R mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the D61Y mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the D61N mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the E69K mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the A72T mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the A72V mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the T73I mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the E76K mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the E76Q mutation in the SHP2 protein.In some embodiments, the SHP2 mutation is the E76G mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the E139D mutation of the SHP2 protein. In some embodiments, the SHP2 mutation is the G506P mutation of the SHP2 protein.
[0142] Myelo-derived suppressor cells (MDSCs) MDSCs are a heterogeneous group of immune cells derived from the myeloid lineage. MDSCs proliferate rapidly in pathological conditions such as chronic infections and cancer, and are distinguished from other myeloid cell types by their potent immunosuppressive activity rather than immunostimulatory properties. CD14 + HLA-DR lo / neg Monocytes, which have reduced HLA-DR expression or no HLA-DR expression at all, are grouped into MDSCs, which can alter adaptive immunity and produce immunosuppression.
[0143] MDSCs accumulate in peripheral blood, lymphoid organs, the spleen, and tumor sites in cancer, infections, chronic inflammation, transplantation, and autoimmunity. While the specific pathways by which tumors recruit, proliferate, and activate MDSCs remain unknown, there is growing evidence for the involvement of interleukins (IL-1β), IL-6, cyclooxygenase 2 (COX2)-producing PGE2, high concentrations of GM-CSF, M-CSF, vascular endothelial growth factor (VEGF), IL-10, transformed growth beta (TGFβ), indoleamine 2,3-dioxygenase (IDO), FLT3 ligands, and stem cell factors.
[0144] Co-culture of immune-competent cells with tumor cell lines that have been shown to induce tolerogenic DCs or MDSCs. Previous studies have also suggested that tumor cells release GM-CSF, which induces granulocyte ROS production and inhibits T cell function. Additionally, programmed death ligand 1 (PD-L1) expression is increased on the surface of MDSCs in mouse tumor models, but the role of this in MDSC-mediated suppression remains unclear.
[0145] Programmed dead ligand 1 (PD-L1) Programmed death ligand 1 (PD-L1, also known as CD274) is an immune checkpoint protein that binds to its receptor, PD-1. PD-L1 is widely expressed in various cell types, primarily in tumor cells, MDSCs, monocytes, macrophages, natural killer (NK) cells, dendritic cells (DCs), and activated T cells, as well as in immune-privileged sites such as the brain, cornea, and retina. Under normal physiological conditions, activation of the PD-1 / PD-L1 signaling pathway is closely related to inducing and maintaining peripheral tolerance, maintaining T cell immune homeostasis, avoiding hyperactivation, and protecting against immune-mediated tissue damage. In pathological conditions, PD-L1 interacts with its receptor, programmed death 1 (PD-1), transmitting negative signals that control a series of processes in the T cell-mediated cellular immune response, including priming, growth, proliferation, and apoptosis, as well as functional maturation, leading to immune evasion.
[0146] Immune checkpoint inhibitors (ICIs) are changing the treatment landscape for many tumors, inducing sustained responses in some cases, and affecting tumor mutation weight and CD8 + T cell density and PD-L1 expression have been proposed as distinct biomarkers of response to PD-1 / -L1 antagonists, respectively. One of the main challenges for immune checkpoint blocking antibodies lies in malignancies or immunologically "cold" tumors with limited T cell responses. These cold tumors contain few invasive T cells, are unrecognized, and do not elicit a robust immune response, making them difficult to treat with current immunotherapies. Surprisingly, we have found that GM-CSF upregulates PD-L1 and contributes to immunosuppressive activity. Transforming "cold" tumors into "hot" tumors represents a breakthrough in cancer treatment.
[0147] GM-CSF antagonists GM-CSF signaling GM-CSF is a pro-inflammatory type I cytokine that enhances the survival and proliferation of a wide range of hematopoietic cell types. It was the first growth factor identified as an inducer of differentiation and proliferation of myeloid cells (e.g., neutrophils, basophils, eosinophils, monocytes, and macrophages) (Wicks IP and Roberts AW. Nat Rev Rheumatol. 2016, 12(1):37-48). Studies using different approaches have demonstrated that GM-CSF overexpression almost always leads to persistent pathological changes (Hamilton JA et al., Growth Factors. 2004, 22(4):225-31). GM-CSF enhances the transport of myeloid cells through activated vascular endothelium and may also contribute to the accumulation of monocytes and macrophages in inflammatory vessels. GM-CSF also promotes the activation, differentiation, survival, and proliferation of monocytes and macrophages, as well as resident tissue macrophages in inflammatory tissue. It modulates the phenotype of antigen-presenting cells in inflammatory tissues by promoting the differentiation of infiltrating monocytes into M1 macrophages and monocyte-derived dendritic cells (MoDCs). Furthermore, IL-23 production by macrophages and MoDCs, in combination with other cytokines such as IL-6 and IL-1, modulates T cell differentiation.
[0148] Together with M-CSF (macrophage-colony-stimulating factor), GM-CSF regulates the number and function of macrophages. Macrophages activated by GM-CSF acquire a range of effector functions, all of which identify them as inflammatory macrophages. GM-CSF-activated macrophages produce pro-inflammatory cytokines, including TNF, IL-1β, IL-6, IL-23, and IL-12, as well as chemokines such as CCL5, CCL22, and CCL24, recruiting T cells and other inflammatory cells into the tissue microenvironment.
[0149] The GM-CSF receptor is a member of the hematopoietin receptor superfamily. It is a heterodimer consisting of alpha and beta subunits. The alpha subunit is highly specific to GM-CSF, while the beta subunit is shared with other cytokine receptors, including IL-3 and IL-5. This is reflected in the broader tissue distribution of the beta receptor subunit. The alpha subunit, GM-CSFRα, is primarily expressed on myeloid and non-hematopoietic cells such as neutrophils, macrophages, eosinophils, dendritic cells, endothelial cells, and respiratory epithelial cells. Full-length GM-CSFRα is a 400-amino acid type I membrane glycoprotein belonging to the type I cytokine receptor family, consisting of a 22-amino acid signal peptide (positions 1-22), a 298-amino acid extracellular domain (positions 23-320), a transmembrane domain from positions 321-345, and a short 55-amino acid intracellular domain. The signal peptide is cleaved to provide the mature form of GM-CSFRα as a 378-amino acid protein. Complementary DNA (cDNA) clones of human and mouse GM-CSFRα are available, and at the protein level, the receptor subunits have 36% identity. GM-CSF can bind to the α subunit alone with relatively low affinity (Kd 1-5 nM), but cannot bind to the β subunit alone at all. However, the presence of both α and β subunits results in a high-affinity ligand-receptor complex (Kd approximately 100 pM). GM-CSF signaling occurs through its initial binding to the GM-CSFRα chain, followed by crosslinking with the larger common β subunit, generating a high-affinity interaction and phosphorylating the JAK-STAT pathway. This interaction can also be signaled through tyrosine phosphorylation and activation of the MAP kinase pathway.
[0150] Pathologically, GM-CSF has been shown to play a role in exacerbating inflammatory, respiratory, and autoimmune diseases. Therefore, neutralization of GM-CSF binding to GM-CSFRα is a therapeutic approach for treating diseases and conditions mediated through GM-CSFR. Accordingly, the present invention relates to binding members that bind to human GM-CSF or GM-CSFRα, or inhibit the binding of human GM-CSF to GM-CSFRα, and / or inhibit signaling resulting from GM-CSF ligand binding to receptors. Upon ligand binding, GM-CSFR induces stimulation of several downstream signaling pathways, including the JAK2 / STAT5, MAPK, and PI3K pathways, all of which are related to the activation and differentiation of myeloid cells. Binding members may be reversible inhibitors of GM-CSF signaling through GM-CSFR.
[0151] GM-CSF antagonists Suitable GM-CSF antagonists for the present invention include therapeutic agents capable of reducing, inhibiting, or inactivating one or more GM-CSF-mediated signaling pathways, including those described herein. For example, suitable GM-CSF antagonists according to the present invention include, but are not limited to, anti-GM-CSF antibodies and their fragments, soluble GM-CSF receptors and their variants, fusion proteins such as GM-CSF soluble receptor-Fc fusion proteins, anti-GM-CSF receptor antibodies or their fragments.
[0152] In some embodiments, preferred GM-CSF antagonists are anti-GM-CSFRα antibodies. Exemplary anti-GM-CSFRα monoclonal antibodies include International Patent Application PCT / GB2007 / 001108, filed March 27, 2007, published as WO2007 / 110631; European Patent Application 120770487, filed October 10, 2010; U.S. Patent Application 11 / 692,008, filed March 27, 2007; U.S. Patent Application 12 / 294,616, filed September 25, 2008; U.S. Patent Application 13 / 941,409, filed July 12, 2013; and November 3, 2010. This includes the descriptions in U.S. Patent Application 14 / 753,792 filed on 0, International Application PCT / EP2012 / 070074 filed on 10 October 2012 and published as WO / 2013 / 053767, International Application PCT / EP2015 / 060902 filed on 18 May 2015 and published as WO2015 / 177097, and International Application PCT / EP2017 / 062479 filed on 23 May 2017, each of which is incorporated herein by their whole reference. In one embodiment, the anti-GM-CSFRα monoclonal antibody is maplilimumab. WO2007 / 110631 reports on the isolation and characterization of maprilumumab and its variants, anti-GM-CSFRα antibodies that share the ability to neutralize the biological activity of GM-CSFRα with high potency. The functional properties of these antibodies are thought to be at least in part due to the binding of the Tyr-Leu-Asp-Phe-Gln motif at positions 226-230 of human GM-CSFRα, thereby inhibiting the association between GM-CSFRα and its ligand GM-CSF. Maprilumumab is a human IgG4 monoclonal antibody designed to modulate macrophage activation, differentiation, and survival by targeting GM-CSFRα. It is a potent antagonist of the biological activity of GM-CSFRα and has been shown to exert its therapeutic effect by binding to GM-CSFRα on leukocytes in the synovial joints of RA patients, resulting in reduced cell survival and activation.The safety profile of the GM-CSFRα antibody mavrilimumab for in vivo use to date has been established in Phase II clinical trials for rheumatoid arthritis (RA).
[0153] In certain embodiments, the antibody is composed of two light chains and two heavy chains. The heavy chain variable domain (VH) contains the amino acid sequence identified in SEQ ID NO: 1. The light chain variable domain (VL) contains the amino acid sequence identified in SEQ ID NO: 2. The heavy chain and light chain each contain a complementarity-determining region (CDR) and a framework region in the following arrangement. FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0154] The mabrilimumab antibody heavy chain contains CDR:HCDR1, HCDR2, and HCDR3 as identified by the amino acid sequences of SEQ ID NOs: 3, 4, and 5, respectively. The light chain contains CDR:LCDR1, LCDR2, and LCDR3 as identified by the amino acid sequences of SEQ ID NOs: 6, 7, and 8, respectively. Amino acid sequence of the variable domain of the anti-GM-CSFRα heavy chain QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWM GGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS(Sequence ID 1) Amino acid sequence of the variable domain of the anti-GM-CSFRα light chain QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL(Sequence ID 2) Amino acid sequence of the anti-GM-CSFRa heavy chain variable domain CDR1 (HCDR1) ELSIH (Sequence ID 3) Amino acid sequence of the anti-GM-CSFRα heavy chain variable domain CDR2 (HCDR2) GFDPEENEIVYAQRFQG (Sequence ID 4) Amino acid sequence of the anti-GM-CSFRα heavy chain variable domain CDR3 (HCDR3) VGSFSPLTLGL(Sequence ID 5) Amino acid sequence of the anti-GM-CSFRα light chain variable domain CDR1 (LCDR1) TGSGSNIGAPYDVS(Sequence ID 6) Amino acid sequence of the anti-GM-CSFRα light chain variable domain CDR2 (LCDR2) HNNKRPS (Sequence ID 7) Amino acid sequence of the anti-GM-CSFRa light chain variable domain CDR3 (LCDR3) ATVEAGLSGSV (Sequence ID 8)
[0155] In one embodiment, the anti-GM-CSFα antibody for cancer treatment is a variant of mabrilimumab selected from GM-CSFα binding members disclosed in international applications WO2007 / 11063 and WO2013053767, which are incorporated whole by reference along with the sequences disclosed therein.
[0156] In some embodiments, the anti-GM-CSFRα antibody for cancer treatment comprises a CDR amino acid sequence having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity with one or more of SEQ ID NOs: 3, SEQ ID NOs: 4, SEQ ID NOs: 5, SEQ ID NOs: 6, SEQ ID NOs: 7, and SEQ ID NOs: 8.
[0157] In some embodiments, the anti-GM-CSFRα antibody includes a light chain variable domain having at least 90% identical amino acid sequence to SEQ ID NO: 2, and a heavy chain variable domain having at least 90% identical amino acid sequence to SEQ ID NO: 1. In some embodiments of the present invention, the anti-GM-CSFRα antibody has a light chain variable domain amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical amino acid sequence to SEQ ID NO: 2, and a heavy chain variable domain amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identical amino acid sequence to SEQ ID NO: 1. In some embodiments of the present invention, the anti-GM-CSFRα antibody comprises a light chain variable domain having the amino acid sequence described in SEQ ID NO: 2 and a heavy chain variable domain having the amino acid sequence described in SEQ ID NO: 1. In some embodiments of the present invention, the heavy chain constant region of the anti-GM-CSFRα antibody comprises CH1, hinge, and CH2 domains derived from an IgG4 antibody fused to a CH3 domain derived from an IgG1 antibody. In some embodiments of the present invention, the heavy chain constant region of the anti-GM-CSFRα antibody is or derived from an IgG1, IgG2, or IgG4 heavy chain constant region. In some embodiments of the present invention, the light chain constant region of the anti-GM-CSFRα antibody is or derived from a lambda or kappa light chain constant region.
[0158] In some embodiments, the anti-GM-CSFRα antibody is a fragment of a maprilumab antibody. In some embodiments, the inhibitor comprises a single-chain variable fragment (ScFv) containing at least one of the CDR sequences of SEQ ID NOs: 3, 4, 5, 6, 7, or 8. In some embodiments, the inhibitor is a fusion molecule containing at least one of the CDR sequences of SEQ ID NOs: 3, 4, 5, 6, 7, or 8. In some embodiments, the anti-GM-CSFRα inhibitor sequence is a bispecific antibody containing at least one of the CDR sequences of SEQ ID NOs: 3, 4, 5, 6, 7, or 8.
[0159] In other embodiments, a preferred GM-CSF antagonist is an anti-GM-CSF antibody. Exemplary anti-GM-CSF monoclonal antibodies include those described in International Application PCT / EP2006 / 004696, filed on 17 May 2006 and published as WO2006 / 122797; International Application PCT / EP2016 / 076225, filed on 31 October 2016 and published as WO2017 / 076804; and International Application PCT / US2018 / 053933, filed on 2 October 2018 and published as WO / 2019 / 070680, each of which includes the sequences disclosed herein, and the whole thereof is incorporated herein by reference. In one embodiment, the anti-GM-CSF monoclonal antibody is otilimab. In one embodiment, the anti-GM-CSF monoclonal antibody is namilumab. In one embodiment, the anti-GM-CSF monoclonal antibody is lenzilumab. In one embodiment, the anti-GM-CSF monoclonal antibody is gimsilumab. In one embodiment, the anti-GM-CSF monoclonal antibody is TJM2.
[0160] The anti-GM-CSFRα or anti-GM-CSF antibodies of this disclosure may be multispecific, e.g., bispecific. The antibodies may be mammalian (e.g., human or mouse), humanized, chimeric, recombinant, synthetically produced, or naturally isolated antibodies. Exemplary antibodies of this disclosure include, but are not limited to, IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgM, IgA (e.g., IgA1, IgA2, and IgAsec), IgD, IgE, Fab, Fab'2, F(ab')2, Fd, Fv, Feb, scFv, scFv-Fc, and SMIP binding moieties. In certain embodiments, the antibody is scFv. The scFv may include, for example, a flexible linker that allows the scFv to be oriented in different directions to enable antigen binding. In various embodiments, the antibody may be a cytosolically stable scFv or intrabody that retains its structure and function in the reducing environment inside the cell (see, for example, Fisher and DeLisa, J.Mol.Biol.385(1):299-311, 2009, incorporated herein by reference). In certain embodiments, the scFv is converted to IgG or a chimeric antigen receptor according to methods known in the art. In embodiments, the antibody binds to both denatured protein targets and native protein targets.
[0161] In most mammals, including humans, an antibody as a whole has at least two heavy (H) chains and two light (L) chains linked by disulfide bonds. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3) and a hinge region between CH1 and CH2. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen.
[0162] Antibodies include all known forms of antibodies, as well as other protein scaffolds with antibody-like properties. For example, an anti-GM-CSFRα antibody may be a monoclonal antibody, polyclonal antibody, human antibody, humanized antibody, bispecific antibody, monovalent antibody, chimeric antibody, or a protein scaffold with antibody-like properties such as fibronectin or ankyrin repeats. Antibodies may have any of the following isotypes: IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgM, IgA (e.g., IgA1, IgA2, and IgAsec), IgD, or IgE.
[0163] An antibody fragment may contain one or more segments derived from an antibody. These antibody-derived segments may retain the ability to specifically bind to a particular antigen. An antibody fragment may be, for example, Fab, Fab', Fab'2, F(ab')2, Fd, Fv, Feb, scFv, or SMIP. An antibody fragment may be, for example, a diabody, triabody, affibody, nanobody, aptamer, domain antibody, linear antibody, single-chain antibody, or any of the diverse multispecific antibodies that can be formed from antibody fragments.
[0164] Examples of antibody fragments include: (i) Fab fragment: a monovalent fragment consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragment: a bivalent fragment containing two Fab fragments linked by disulfide crosslinks at a hinge region; (iii) Fd fragment: a fragment consisting of a VH domain and a CH1 domain; (iv) Fv fragment: a fragment consisting of the VL domain and VH domain of a single arm of the antibody; (v) dAb fragment: a fragment containing a VH domain and a VL domain; (vi) dAb fragment: a fragment that is a VH domain; (vii) dAb fragment: a fragment that is a VL domain; (viii) an isolated complementarity-determining region (CDR); and (ix) a combination of two or more isolated CDRs that can be optionally bound by one or more synthetic linkers. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be conjugated, for example, using a recombination method with a synthetic linker that allows the VL and VH regions to be paired together to form a monovalent binding portion (known as single-chain Fv (scFv)) and expressed as a single protein. Antibody fragments can be obtained using prior art known to those skilled in the art and, in some examples, can be used in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact immunoglobulins. Antibody fragments may further comprise any of the antibody fragments described above, with the addition of additional C-terminal amino acids, N-terminal amino acids, or amino acids that separate individual fragments.
[0165] An antibody may be called a chimeric antibody if it contains one or more antigenic determinant regions or constant regions derived from a first species and one or more antigenic determinant regions or constant regions derived from a second species. Chimeric antibodies may be constructed, for example, by genetic engineering. Chimeric antibodies may contain immunoglobulin gene segments belonging to different species (e.g., from mouse and human).
[0166] The antibody may be a human antibody. A human antibody refers to a binding site having a variable region in which both the framework region and the CDR region are derived from a human immunoglobulin sequence. Furthermore, if the antibody includes a constant region, the constant region is also derived from a human immunoglobulin sequence. A human antibody may contain, for example, one or more sequence variations, such as mutations, of amino acid residues not specified in the human immunoglobulin sequence. Variations or additional amino acids may be introduced, for example, by human manipulation. The human antibodies of this disclosure are not chimeric.
[0167] An antibody may be humanized, and an antibody containing one or more antigen-determining regions (e.g., at least one CDR) substantially derived from a non-human immunoglobulin or antibody means that it has been manipulated to contain at least one immunoglobulin domain substantially derived from a human immunoglobulin or antibody. An antibody may be humanized using the conversion methods described herein, for example, by inserting an antigen-recognition sequence from a non-human antibody encoded by a first vector into a human framework encoded by a second vector. For example, the first vector may contain a polynucleotide encoding a non-human antibody (or a fragment thereof) and a site-specific recombination motif, while the second vector may contain a polynucleotide encoding a human framework and a site-specific recombination motif complementary to the site-specific recombination motif on the first vector. The site-specific recombination motif may be positioned on each vector such that a recombination event results in the insertion of one or more antigen-determining regions from a non-human antibody into the human framework, thereby forming a polynucleotide encoding a humanized antibody.
[0168] In certain embodiments, antibodies are converted from scFv to IgG (e.g., IgG1, IgG2, IgG3, and IgG4). Various methods exist in the art for converting scFv fragments to IgG. One such method for converting scFv fragments to IgG is disclosed in U.S. Patent Application Publication No. 2016 / 0362476, which is incorporated herein by reference.
[0169] Combination therapy Immune checkpoint inhibitors (ICIs) In some embodiments, a method for treating cancer according to the present invention includes administering a GM-CSF antagonist in combination with an ICI to a subject in need thereof.
[0170] In some embodiments, the ICI is a biopharmaceutical or small molecule. In some embodiments, the ICI is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein, or a combination thereof.
[0171] In some embodiments, ICI inhibits checkpoint proteins that may be CTLA-4, PD-L1, PD-L2, PD-1, B7-H3, B7-H4, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, B-7 family ligands, or combinations thereof. In some embodiments, ICI interacts with ligands of checkpoint proteins that may be CTLA-4, PD-L1, PD-L2, PD-1, B7-H3, B7-H4, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, B-7 family ligands, or combinations thereof.
[0172] In some embodiments, ICI is an anti-CTLA-4 antibody. In some embodiments, ICI is an anti-PD-L1 antibody. In some embodiments, ICI is an anti-PD-L2 antibody. In some embodiments, ICI is an anti-PD-1 antibody. In some embodiments, ICI is an anti-B7-H3 antibody. In some embodiments, ICI is an anti-B7-H4 antibody. In some embodiments, ICI is an anti-BTLA antibody. In some embodiments, ICI is an anti-HVEM antibody. In some embodiments, ICI is an anti-TIM-3 antibody. In some embodiments, ICI is an anti-GAL-9 antibody. In some embodiments, ICI is an anti-LAG-3 antibody. In some embodiments, ICI is an anti-VISTA antibody. In some embodiments, ICI is an anti-KIR antibody. In some embodiments, ICI is an anti-2B4 antibody. In some embodiments, ICI is an anti-CD160 antibody. In some embodiments, ICI is an anti-CGEN-15049 antibody. In some embodiments, the ICI is an anti-CHK1 antibody. In some embodiments, the ICI is an anti-CHK2 antibody. In some embodiments, the ICI is an anti-A2aR antibody. In some embodiments, the checkpoint inhibitor is an anti-B-7 antibody.
[0173] In some embodiments, the PD-1 antibody is pembrolizumab. In some embodiments, the PD-1 antibody is nivolumab. In some embodiments, the PD-1 antibody is cemiprimab. In some embodiments, the PD-L1 antibody is atezolizumab. In some embodiments, the PD-L1 antibody is avelumab. In some embodiments, the PD-L1 antibody is durvalumab. In some embodiments, the CTLA-4 antibody is ipilimumab.
[0174] Additional treatments In some embodiments, a method for treating cancer according to the present invention comprises administering a GM-CSF antagonist in combination with an additional therapeutic agent to a subject in need thereof. In certain embodiments, the additional agent is a cancer therapy comprising chemotherapy and / or radiotherapy. In certain embodiments, the additional therapeutic agent comprises a recombinant protein or a monoclonal antibody. In certain embodiments, the recombinant protein or monoclonal antibody includes etaracizumab (Abegrin), tacuzumab tetraxetan, bevacizumab (Avastin), rabetuzumab, cetuximab (Erbitux), obinutuzumab (Gazyva), trastuzumab (Herceptin), clivatuzumab, trastuzumab emtansine (Kadcyla), ramucirumab, rituximab (MabThera, Rituxan), gemtuzumab ozogamicin (Mylotarg), pertuzumab (Omnitarg), girentuximab (Rencarex), or nimotuzumab (Theracim, Theraloc).
[0175] In certain embodiments, the GM-CSF antagonist includes an immunomodulator that targets a checkpoint inhibitor as described in the Checkpoint Inhibitors section above. In certain embodiments, the immunomodulator includes nivolumab, ipilimumab, atezolizumab, or pembrolizumab. In certain embodiments, the additional therapeutic agent is a chemotherapeutic agent. In certain embodiments, the chemotherapeutic agent is an alkylating agent (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechloretamine, uramustine, thiotepa, nitrosourea, or temozolomide), anthracycline (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, or mitoxantrone), cytoskeletal disruption agent (e.g., paclitaxel or docetaxel), histone deacetylase inhibitor (e.g., vorinostat or romidepsin), topoisomerase inhibitor (e.g., irinotecan, topotecan, amsacrin, etoposide, or teniposide), kinase inhibitor (e.g., These include bortezomib, erlotinib, gefitinib, imatinib, vemurafenib, or bismodegib), nucleoside analogs or precursor analogs (e.g., azacitidine, azathioprine, capecitabine, cytarabine, fluorouracil, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, or thioguanine), peptide antibiotics (e.g., actinomycin or bleomycin), platinum-based drugs (e.g., cisplatin, oxaloplatin, or carboplatin), or plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, or docetaxel). In some embodiments, the chemotherapeutic agent is a nucleoside analog. In some embodiments, the chemotherapeutic agent is gemcitabine. In certain embodiments, the additional therapeutic agent is radiotherapy.
[0176] Cancer treatment The present invention can be used to treat various cancers, particularly those that are refractory or resistant to immune checkpoint inhibitors (ICIs), or terminal or metastatic cancers.
[0177] In some embodiments, cancer is any solid tumor or humoral cancer, including genitourinary cancers (such as prostate cancer, renal cell carcinoma, and bladder cancer), gynecological cancers (such as ovarian cancer, cervical cancer, and endometrial cancer), lung cancer, gastrointestinal cancers (such as non-metastatic or metastatic colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, hepatocellular carcinoma, and cholangiocarcinoma), head and neck cancers (e.g., head and neck squamous cell carcinoma), brain cancer including malignant gliomas and brain metastases, malignant mesothelioma, non-metastatic or metastatic breast cancer (e.g., hormone-refractory metastatic breast cancer), malignant melanoma, Merkel cell carcinoma, or bone and soft tissue sarcoma, as well as hematological malignancies such as multiple myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndromes, and acute lymphoblastic leukemia. In some embodiments, the disease is non-small cell lung cancer (NSCLC), breast cancer (e.g., stage IV breast cancer, hormone-refractory metastatic breast cancer), head and neck cancer (e.g., head and neck squamous cell carcinoma), metastatic colorectal cancer, hormone-sensitive or hormone-refractory prostate cancer, colorectal cancer (e.g., stage IV colorectal cancer), ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, soft tissue sarcoma, or small cell lung cancer.
[0178] As used herein, the term “cancer” refers to a broad class of disorders characterized by hyperproliferative cell growth, either in vitro (e.g., in transformed cells) or in vivo. Conditions that can be treated or prevented by the compositions and methods of the present invention include a variety of neoplasms, including, for example, benign or malignant tumors and various hyperplasias. The compounds and methods of the present invention can achieve inhibition and / or reversal of undesirable hyperproliferative cell growth associated with such conditions.
[0179] Examples of cancer include acute lymphoblastic leukemia (adult); acute lymphoblastic leukemia (child); acute myeloid leukemia (adult); adrenocortical carcinoma (adrenal cortical carcinoma) (child); AIDS-associated lymphoma (AIDS-associated malignant tumor); anal cancer; astrocytoma (childhood cerebellar); astrocytoma (childhood cerebral); extrahepatic cholangiocarcinoma (bile duct cancer); bladder cancer (child); bone cancer, osteosarcoma / malignant fibrous histiocytoma; brainstem glioma (child); brain tumor (adult); brain tumor, brainstem glioma (child); brain tumor (child) Astrocytoma, pediatric; brain tumor, cerebral astrocytoma / malignant glioma, pediatric; brain tumor, ependymoma, pediatric; brain tumor, medulloblastoma, pediatric; brain tumor, supratentorial primitive neuroectodermal tumor, pediatric; brain tumor, visual tract and hypothalamic glioma, pediatric; brain tumor, pediatric (other); breast cancer; breast cancer and pregnancy; breast cancer, pediatric; breast cancer, male; bronchial adenoma / carcinoid, pediatric; carcinoid tumor, pediatric; carcinoid tumor, gastrointestinal; carcinoma, adrenal cortex; carcinoma, pancreas Islet cells; carcinoma of unknown primary origin; primary central nervous system lymphoma; cerebellar astrocytoma, pediatric; cerebral astrocytoma / malignant glioma, pediatric; cervical cancer; childhood cancer; chronic lymphocytic leukemia; chronic myeloid leukemia; chronic myelomonocytic leukemia (CMML); juvenile myelomonocytic leukemia (JMML); chronic myeloproliferative disorder; clear cell sarcoma of the tendon sheath; colon cancer; colorectal cancer, pediatric; cutaneous T-cell lymphoma; endometrial cancer; ependymoma, pediatric; epithelial carcinoma, ovary; esophagus Cancer; Esophageal cancer, pediatric; Ewing's tumor family; Extracranial germ cell tumors, pediatric; Extragonadal germ cell tumors; Extrahepatic cholangiocarcinoma; Eye cancer, intraocular melanoma; Eye cancer, retinoblastoma; Gallbladder cancer; Gastric (stomach) cancer; Gastric (stomach) cancer, pediatric; Gastrointestinal carcinoid tumors; Germ cell tumors, extracranial, pediatric; Germ cell tumors, extragonadal; Germ cell tumors, ovarian; Germ trophoblastic tumors; Glioma. Pediatric brainstem; Glioma. Pediatric visual tract and hypothalamic cancer; hairy cell leukemia; head and neck cancer; hepatocellular carcinoma, adult (primary); hepatocellular carcinoma, pediatric (primary); Hodgkin lymphoma, adult; Hodgkin lymphoma, pediatric; Hodgkin lymphoma during pregnancy; hypopharyngeal cancer; hypothalamic and visual tract glioma, pediatric; intraocular melanoma; islet cell carcinoma (endocrine part of the pancreas); Kaposi's sarcoma; kidney cancer; laryngeal cancer; laryngeal cancer, pediatric; leukemia, acute lymphoblastic, adult; leukemia, acute lymphoblastic, pediatric; leukemia, acute bone marrow, adult; leukemia, acute bone marrow, pediatric;Leukemia, chronic lymphocytic; Leukemia, chronic myeloid; Leukemia, hairy cell; Lip and oral cancer; Liver cancer, adult (primary); Liver cancer, pediatric (primary); Lung cancer, non-small cell; Lung cancer, small cell; Lymphoblastic leukemia, adult acute; Lymphoblastic leukemia, pediatric acute; Lymphoblastic leukemia, chronic; Lymphoma, AIDS-related; Lymphoma, central nervous system (primary); Lymphoma, cutaneous T cell; Lymphoma, Hodgkin, adult; Lymphoma, Hodgkin, pediatric; Lymphoma, Hodgkin during pregnancy; Lymphoma, non-Hodgkin, adult; Lymphoma, non-Hodgkin, pediatric; Lymphoma, non-Hodgkin during pregnancy; Lymphoma, primary central nervous system; Macroglobulinemia, Waldens Träme; Male breast cancer; Malignant mesothelioma, adult; Malignant mesothelioma, pediatric; Malignant thymoma; Medulloblastoma, pediatric; Melanoma; Intraocular melanoma; Merkel cell carcinoma; Malignant mesothelioma; Metastatic squamous cell carcinoma of unknown primary origin; Multiple endocrine neoplasia syndrome, pediatric; Multiple myeloma / plasmacytic neoplasm; Mycosis fungoides; Myelodysplastic syndrome; Chronic myeloid leukemia; Acute myelopathy, pediatric; Multiple myeloma; Chronic myeloproliferative disorder; Nasal and paranasal sinus cancer; Nasopharyngeal cancer; Nasopharyngeal cancer, pediatric; Neuroblastoma; Neurofibroma; Non-Hodgkin lymphoma, adult; Non-Hodgkin lymphoma, pediatric; Non-Hodgkin lymphoma during pregnancy; Non-small cell lung cancer; Oral cancer, pediatric; Oral Cavity and lip cancer; oropharyngeal cancer; osteosarcoma / malignant fibrous histiocytoma of bone; ovarian cancer, pediatric; ovarian epithelial carcinoma; ovarian germ cell tumor; low-grade ovarian tumor; pancreatic cancer; pancreatic cancer, pediatric, pancreatic cancer, islet cell tumor; paranasal sinus and nasal cavity cancer; parathyroid cancer; penile cancer; pheochromocytoma, pineal and supratentorial primitive neuroectodermal tumors, pediatric; pituitary tumor; plasma cell neoplasms / multiple myeloma; pleuropulmonary blastoma; pregnancy and breast cancer; pregnancy and Hodgkin lymphoma; pregnancy and non-Hodgkin lymphoma; primary central nervous system lymphoma; primary liver cancer, Adults; Primary liver cancer; Children; Prostate cancer; Rectal cancer; Renal cell carcinoma (kidney cancer); Renal cell carcinoma, Children; Transitional cell carcinoma of the renal pelvis and ureter; Retinoblastoma; Rhabdomyosarcoma, Children; Salivary gland cancer; Salivary gland cancer, Children; Sarcoma, Ewing's tumor family; Sarcoma, Kaposi's; Sarcoma (osteosarcoma) / Malignant fibrous histiocytoma of bone; Sarcoma, Rhabdomyosarcoma, Children; Sarcoma, Soft tissue, Adults; Sarcoma, Soft tissue, Children; Sézary syndrome; Skin cancer; Skin cancer, Children; Skin cancer (melanoma); Skin cancer, Merkel cells; Small cell lung cancer; Small intestine cancer;Examples include soft tissue sarcoma, adult; soft tissue sarcoma, pediatric; squamous cell carcinoma of unknown primary origin, metastatic; stomach cancer; stomach cancer, pediatric; supratentorial primitive neuroectodermal tumor, pediatric; T-cell lymphoma, cutaneous; testicular cancer; thymoma, pediatric; malignant thymoma; thyroid cancer; thyroid cancer, pediatric; transitional cell carcinoma of the renal pelvis and ureter; gestational trophoblastic neoplasm; cancer of unknown primary site, pediatric; unusual cancer in children; transitional cell carcinoma of the ureter and renal pelvis; urethral cancer; uterine sarcoma; vaginal cancer; visual pathway and hypothalamic glioma, pediatric; vulvar cancer; Waldenström macroglobulinemia; and Wilms' tumor.
[0180] Chronic myeloid leukemia (CML) affects bone marrow cells in the blood and bone marrow, while chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) affect specific bone marrow cells called monocytes, which help fight infections. In CMML, the median age at diagnosis is 65–75 years. Common symptoms of CMML include weakness, fatigue, unexplained bruising and / or bleeding, infections, and hepatomegaly and / or spleen enlargement. CMML is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocyte cells, and an increased risk of progression to acute leukemia. In some embodiments, the present invention provides a method for treating CMML in a patient, comprising administering a therapeutically effective dose of a GM-CSF antagonist to a patient in need of treatment, wherein the administration improves, stabilizes, and reduces one or more symptoms of CMML compared to a control. In the 2016 World Health Organization (WHO) classification of myeloid neoplasms, chronic myelomonocytic leukemia (CMML), classified as a clonal hematopoietic stem cell disorder, is characterized by dysplastic features in the bone marrow (BM) and the presence of persistent (>3 months) peripheral blood (PB) monocytosis (≧1×10⁻¹⁰ 9It is defined as being characterized by a white blood cell count of ≥13 × 10¹⁰ / L (monocytes ≥10%). Following the overlapping features of both myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN), the classification of CMML as a unique myeloid neoplasm has undergone several changes, dating back to the original efforts of the French-American-British (FAB) joint group in 1982. With new evidence showing clinical, morphological, and molecular differences, the 2016 WHO classification now defines MPN-CMML as ≥13 × 10¹⁰ 9 White blood cell count / L, <13 × 10 for MDS-CMML 9 It is again recommended to classify CMML into “proliferative” (MPN-CMML) and “dysplastic” (MDS-CMML) subtypes based on the white blood cell count in / L. In some embodiments, GM-CSF antagonists are administered to patients with CMML, and the CMML is classified as MPN-CMML. In some embodiments, GM-CSF antagonists are administered to patients with CMML, and the CMML is classified as MDS-CMML. Furthermore, based on PB and BM blast percentages, CMML can be classified into three categories: (a) CMML-0 (<2% PB blasts including promonocytes, and <5% BM blasts), (b) CMML-1 (2-4% PB blasts including promonocytes, and 5-9% BM blasts), and (c) CMML-2 (>5% PB blasts including promonocytes, 10-19% BM blasts, and / or any Auer's bodies present). CMML fatality is ultimately caused by 1) bone marrow failure, 2) breakthrough opportunistic infections (in the majority of patients), 3) conversion to AML, and / or 4) thrombosis / thrombosis. In some embodiments, a GM-CSF antagonist is administered to patients with CMML, and CMML is classified as CMML-0. In some embodiments, a GM-CSF antagonist is administered to patients with CMML, and CMML is classified as CMML-1. In some embodiments, a GM-CSF antagonist is administered to patients with CMML, and CMML is classified as CMML-2.
[0181] CMML frequently progresses to acute myeloid leukemia (AML). 15–30% of patients progress to AML, at which point survival rates drop to 4.7 months without hematopoietic stem cell transplantation (HCT) and 14.3 months with HCT. One known prognostic factor regarding survival is the CMML subtype. Dysplastic and proliferative subtypes have significantly different effects on patients: patients with the dysplastic subtype have low blood cell counts, and their natural course and clinical problems related to bone marrow failure are similar to those of MDS patients, while patients with the proliferative subtype have high blood cell counts and often have systemic symptoms or symptoms associated with organomegaly. Patients with the proliferative form of the disease have shorter survival times and a higher risk of transformation to AML. In some embodiments, administration of GM-CSF antagonists to patients with CMML shortens the time to AML or prevents it from progressing.
[0182] JMML is most commonly diagnosed in infants and children under 6 years of age. Common symptoms of JMML include bruising, developmental delay, loss of appetite, irritability, abdominal distension, dry cough, rash, hepatomegaly and / or splenomegaly, and lymphadenopathy. In some embodiments, the present invention provides a method for treating JMML in a patient, comprising administering a therapeutically effective dose of a GM-CSF antagonist to a patient in need of treatment, wherein the administration improves, stabilizes, and reduces one or more symptoms of JMML compared to a control. In some embodiments, administration of a GM-CSF antagonist to a patient with JMML shortens the time to AML or prevents AML from occurring.
[0183] Pharmaceutical composition and administration The antibodies or drugs of the present invention (also referred to herein as “active compounds”) and their derivatives, fragments, analogs, and homologs may be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the antibody or drug and a pharmaceutically acceptable carrier. As used herein, the term “pharmaceutically acceptable carrier” is intended to include any solvent, dispersion medium, coating, antibacterial and antifungal agent, isotonic agent, and absorption retarder, etc., that are compatible with pharmaceutical administration. Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, the standard reference text of the art, incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, physiological saline, Ringer’s solution, dextrose solution, and 5% human serum albumin. Non-aqueous vehicles such as liposomes and fixative oils may also be used. The use of such media and drugs for pharmaceutically active substances is well known in the art. Unless any conventional media or drug is incompatible with the active compound, its use in the composition is intended. Complementary active compounds may also be incorporated into the composition.
[0184] The pharmaceutical compositions of the present invention are formulated to suit their intended route of administration. Examples of routes of administration include parenteral administration, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain the following components: sterile diluents such as water for injection, saline solution, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates, or phosphates; and agents for adjusting osmotic pressure such as sodium chloride or dextrose. The pH may be adjusted with an acid or base such as hydrochloric acid or sodium hydroxide. Parenteral preparations may be sealed in ampoules, disposable syringes, or multi-dose vials made of glass or plastic.
[0185] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (if water-soluble) or dispersions and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Adequate fluidity can be maintained, for example, by the use of coatings such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. In many cases, it is preferable to include isotonic agents in the composition, such as sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride. Long-term absorption of injectable compositions can be achieved by including absorption-delaying agents, such as aluminum monostearate and gelatin, in the composition.
[0186] Sterile injectable solutions can be prepared by incorporating the active compound, along with one or a combination of the components listed above as needed, in the required amounts in a suitable solvent, followed by sterilization by filtration. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other components required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and lyophilization, which yield a powder of the active component plus any additional desired components from its previously sterile filtered solution.
[0187] Oral compositions generally contain an inert diluent or food carrier. These may be encapsulated in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of tablets, lozenges, or capsules. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash, in which the compound in the fluid carrier is applied orally, swished, spat out, or swallowed. Pharmaceutically compatible binders and / or adjuvant materials may be included as part of the composition. Tablets, capsules, lozenges, etc., may contain any of the following ingredients: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate or Sterotes; flow promoters such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavoring, or compounds of similar properties.
[0188] For administration by inhalation, the compound is delivered in the form of an aerosol spray from a pressurized container or dispenser containing a suitable propellant, such as a gas like carbon dioxide, or a nebulizer.
[0189] Systemic administration may also be by mucosal or dermal means. For mucosal or dermal administration, a suitable penetrating agent for the barrier to be permeated is used in the formulation. Such penetrating agents are generally known in the art and include, for example, those for mucosal administration, detergents, bile salts, and fusidic acid derivatives. Mucosal administration can be achieved through the use of nasal sprays or suppositories. For dermal administration, the active compound is formulated into ointments, salves, gels, or creams, which are generally known in the art.
[0190] The compounds can also be prepared in the form of suppositories for rectal delivery (e.g., using conventional suppository bases such as cocoa butter and other glycerides) or retention enemas.
[0191] In one embodiment, the active compound is prepared with a carrier that will protect the compound from rapid removal from the body, such as a controlled-release formulation comprising a graft and a microencapsulated delivery system. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoester, and polylactic acid may be used. Methods for preparing such formulations will be obvious to those skilled in the art. The materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions (containing liposomes targeted to infected cells with monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0192] For ease of administration and uniformity of dosage, it is particularly advantageous to formulate oral or parenteral compositions in dosage unit forms. As used herein, a dosage unit form refers to a physically distinct unit suitable as a unit dose for the subject to be treated, each unit containing a predetermined amount of the active compound calculated to produce the desired therapeutic effect in relation to the required pharmaceutical carrier. The specifications for the dosage unit forms of the present invention depend on and directly on the inherent characteristics of the active compound, the specific therapeutic effect to be achieved, and the limitations inherent in the technique of formulating such active compounds for the treatment of an individual.
[0193] The pharmaceutical composition may be contained in a container, pack, or dispenser along with the instructions for administration.
[0194] In some embodiments, the therapeutically effective dose of the GM-CSF antagonist is approximately 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, or 250 mg. In some embodiments, the therapeutically effective dose is approximately 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 70 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 650 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, or 800 mg.
[0195] In some embodiments, the therapeutically effective dose is approximately 225 mg. In some embodiments, the therapeutically effective dose is approximately 375 mg. In some embodiments, the therapeutically effective dose is approximately 450 mg. In some embodiments, the therapeutically effective dose is approximately 750 mg.
[0196] In some embodiments, the therapeutically effective dose of the GM-CSF antagonist is between 0.1 mg / kg and 15 mg / kg. In some embodiments, the therapeutically effective dose is between 2 mg / kg and 10 mg / kg. In some embodiments, the therapeutically effective dose is between 3 mg / kg and 10 mg / kg. In some embodiments, the therapeutically effective dose is between 5 mg / kg and 10 mg / kg. In some embodiments, the therapeutically effective dose is between 6 mg / kg and 10 mg / kg. In some embodiments, the therapeutically effective dose is approximately 1 mg / kg. In some embodiments, the therapeutically effective dose is approximately 2 mg / kg. In some embodiments, the therapeutically effective dose is approximately 3 mg / kg. In some embodiments, the therapeutically effective dose is approximately 4 mg / kg. In some embodiments, the therapeutically effective dose is approximately 5 mg / kg. In some embodiments, the therapeutically effective dose is approximately 6 mg / kg. In some embodiments, the therapeutically effective dose is approximately 7 mg / kg. In some embodiments, the therapeutically effective dose is approximately 8 mg / kg. In some embodiments, the therapeutically effective dose is approximately 9 mg / kg. In some embodiments, the therapeutically effective dose is approximately 10 mg / kg. In some embodiments, the therapeutically effective dose is approximately 11 mg / kg. In some embodiments, the therapeutically effective dose is approximately 12 mg / kg. In some embodiments, the therapeutically effective dose is approximately 15 mg / kg.
[0197] In some embodiments, the GM-CSF antagonist is administered at specific dosing intervals. In some embodiments, the dosing interval is once a week.
[0198] In some embodiments, the dosing interval is at least 5 days.
[0199] In some embodiments, the administration interval is once every two weeks.
[0200] In some embodiments, the administration interval is once every three weeks.
[0201] In some embodiments, the administration interval is once every four weeks.
[0202] In some embodiments, the administration interval is once every five weeks.
[0203] In certain embodiments, the GM-CSF antagonist is administered intravenously.
[0204] In some embodiments, the GM-CSF antagonist is administered as an initial loading dose, followed by at least one maintenance dose. In some embodiments, the maintenance dose is lower than the initial loading dose. In some embodiments, the maintenance dose is higher than the initial loading dose. In some embodiments, the maintenance dose is lower than the initial loading dose. [Examples]
[0205] The present invention is further illustrated by, but not limited to, the slides accompanying this specification. While specific compounds, compositions, and methods of the present invention are described specifically according to specific embodiments, the following examples are for illustrative purposes only and are not intended to limit the present invention.
[0206] Example 1. Anti-GM-CSFRα antibody rescues T cell proliferation. The study in this embodiment illustrates that the ability of the bone marrow population to suppress T cell proliferation can be rescued by GM-CSF antagonists.
[0207] T cell proliferation assays were performed using CD14+ cells with and without anti-GM-CSFRα antibody treatment. Briefly, CD14+ (MDSC) cells were isolated from blood samples (PBMCs) obtained from pancreatic cancer patients according to methods known in the art. The isolated CD14+ cells were treated with 100 μg / mL anti-GM-CSFRα antibody for 48 hours. Next, CD3+ T cells labeled with carboxy-fluorescein diacetate succinimimidyl ester (CFSE) were co-cultured with anti-GM-CSFRα antibody-treated or untreated CD14+ cells for 96 hours, and proliferation was determined by CFSE dilution (divided cells). T cells without co-culture were used as negative controls.
[0208] As shown in Figure 1, T cell proliferation is significantly suppressed after culturing with untreated CD14+ cells. On the other hand, CD14+ cells treated with anti-GM-CSFRα antibody showed increased T cell proliferation, suggesting that the addition of anti-GM-CSFRα antibody rescues T cell proliferation and inhibits the suppression of MDSCs.
[0209] Example 2. Cancer cell conditioning medium polarizes monocytes into phenotypic MDSCs. In this study, various cancer cell lines were incubated with CD+14 monocytes using a conditional medium from GM-CSF-expressing cancer cells, and the resulting phenotype was observed in MDSCs (HLA-DR 低 This was used to illustrate the increase in ).
[0210] Cancer cell lines were analyzed for GM-CSF expression. In this particular study, GM-CSF expression was measured in two colorectal cancer (HCT116 and SW-480), two pancreatic cancer (Panc-1 and Capan-1), cervical adenocarcinoma (HeLa), and malignant melanoma (A375) cell lines. Of the cell lines tested, SW-480, CAPAN-1, HCT116, and PANC-1 had KRAS mutations, A375 had RAF mutations, and HeLa was RAS / RAF wild-type. As shown in Figure 2, cancer cell lines express GM-CSF at different levels. In particular, GM-CSF expression was relatively high in the KRAS-mutated cancer cell lines SW480 and Capan-1, and relatively low in HeLa cells lacking KRAS mutations.
[0211] To generate tumor condition medium (CM), cell lines were seeded and cultured according to methods known in the art. CD14+ cells were then cultured in the presence of CM for 6 days, and gene and protein expression were analyzed. Low levels of the HLA-DR biomarker indicate the MDSC phenotype. Figure 3 shows the increase in phenotypic MDSCs when CD14+ monocytes were incubated with the condition medium from GM-CSF-expressing cancer cells compared to CD+14 cells grown in normal culture medium. The results indicate that CM from cancer cell lines with high GM-CSF expression induces high levels of MDSCs, suggesting that GM-CSF contributes to the polarization of monocytes into the phenotypic MDSC.
[0212] Example 3. Anti-GM-CSFRα antibody blocks PD-L1 upregulation in MDSCs. This study exemplifies the inventors' remarkable discovery that GM-CSF induces PD-L1 expression on phenotypic MDSCs. In particular, treatment with a GM-CSF antagonist is sufficient to suppress PD-L1 expression on monocytes treated with conditional medium (CM) from GM-CSF-expressing cancer cell lines.
[0213] One of the main challenges for immune checkpoint blocking antibodies lies in malignant tumors or immunologically "cold" tumors with limited T cell responses. These cold tumors contain few invasive T cells, are unrecognized, and do not elicit a robust immune response, making them difficult to treat with current immunotherapies. Surprisingly, we have found that GM-CSF upregulates PD-L1, a checkpoint protein on the surface of MDSCs that contributes to immunosuppressive activity. This study demonstrates that anti-GM-CSFRα antibodies can be used to transform "cold" tumors into "hot" tumors, potentially increasing the efficacy and sensitivity of immunotherapy.
[0214] In this study, various cancer cell lines were used to evaluate changes in PD-L1 expression levels on MDSCs when CD14+ monocytes were incubated with conditional media from GM-CSF-expressing cancer cells. As shown in Figure 4, adding conditional media from GM-CSF-expressing cancer cell lines to CD14+ monocytes increased PD-L1 expression levels compared to baseline (culture medium only). HeLa cell lines exhibiting low levels of GM-CSF expression (see Figure 2) did not upregulate PD-L1 expression. Addition of recombinant GM-CSF combined with CM (CM+GM-CSF) increased PD-L1 expression, indicating that GM-CSF induces PD-L1 expression on phenotypic MDSCs. The spike in PD-L1 was more pronounced in cell lines with low baseline PD-L1 expression with CM alone (e.g., Panc-1 and HeLa cells). The effect of anti-GM-CSFRα antibodies on PD-L1 expression was also investigated. Treatment of MDSCs with anti-GM-CSFRα antibodies in CM (CM+Ab and CM+GM-CSF+Ab, respectively) in the absence or presence of recombinant GM-CSF resulted in significantly reduced levels of PD-L1 compared to CM alone or CM+GM-CSF, respectively. These data indicate that anti-GM-CSFRα antibodies suppress PD-L1 upregulation in CD14+ monocytes (MDSCs) treated with conditional media from GM-CSF-expressing cancer cell lines.
[0215] Example 4. Anti-GM-CSFRα antibody suppresses PD-L1 expression in MDSCs. This study demonstrates that, when PD-L1 levels on MDSCs are already elevated, GM-CSF antagonists can suppress PD-L1 expression on MDSCs treated with a conditional medium derived from GM-CSF-expressing cancer cell lines (CMs), regardless of whether the GM-CSF antagonist is added concurrently with or after CM treatment.
[0216] As shown in Figure 5A, conditional media (shown in Table 1) from GM-CSF cancer cell lines (CM) containing or not containing recombinant GM-CSF (at 10 ng / mL) and anti-GM-CSFRα antibody (at 100 μg / mL) were added to CD14+ monocytes (MDSCs) on day 1. After 3 days of incubation, MDSC cells were analyzed for PD-L1 expression. [Table 1]
[0217] Consistent with Example 3, the addition of conditional media from GM-CSF-expressing cancer cell lines to MDSCs (B; CM) or CM containing recombinant GM-CSF (D; CM+GM-CSF) increased the level of PD-L1 expression compared to baseline (A; culture medium only). Furthermore, as shown in samples C and E in Figure 5A, a decrease in PD-L1 was observed when anti-GM-CSFRα antibodies were added simultaneously with CM or CM+GM-CSF, suggesting that anti-GM-CSFRα antibodies block the upregulation of PD-L1 in MDSCs.
[0218] Next, we investigated the effect of adding anti-GM-CSFRα antibody after incubation of MDSCs using conditional media to examine the effect of GM-CSF blockade on PD-L1 expression levels, given that elevated PD-L1 levels in MDSCs were already established. In this specific setup, MDSCs were cultured for 48 hours in conditional media with or without recombinant GM-CSF (samples B-E in Figure 5B). Then, on day 3, anti-GM-CSFRα antibody was added to samples C and E in Figure 5B (after 48 hours). MDSCs in sample A were incubated in culture medium for 3 days as a control. Phenotypic analysis of MDSCs was performed on day 4. As shown in Figure 5B, treatment of MDSCs with anti-GM-CSFRα antibody after they had been cultured using conditional media from GM-CSF-expressing cancer cell lines (samples C and E) suppressed the expression level of PD-L1 on the MDSCs. Notably, just 24 hours after treatment with anti-GM-CSFRα antibody, PD-L1 expression in samples C and E was reduced compared to samples B and D, respectively.
[0219] Example 5. Anti-GM-CSFRα antibody reduces MDSC-mediated T cell suppression. The study in this embodiment further illustrates that the ability of the bone marrow population to suppress T cell proliferation can be inhibited by GM-CSF antagonists.
[0220] In this particular experiment, monocytes treated with a conditional medium from a GM-CSF-expressing cancer cell line were used in a T cell proliferation assay. Briefly, monocytes were cultured for 3 days in a conditional medium from a GM-CSF-expressing cancer cell line (CM) (CM-treated monocytes). CD8+ T cells (1 × 10⁶) 5T cells were prepared by labeling them with CFSE and stimulating them with IL-2 and soluble CD3 / CD28 T cell activator in IMDM cell culture medium. As shown in Figure 6A, on day 3, stimulated T cells were co-cultured with CM-treated monocytes (in a 2:1 monocyte:T cell ratio) with or without anti-GM-CSFRα antibody (100 μg / mL) in a mixed lymphocyte reaction. The T cells were grown for 5 days, and cell proliferation was evaluated by flow cytometry using CFSE dilutions of CD4+ and CD8+ T cells, which are markers for helper T cells and cytotoxic T cells. Figure 6A shows that the anti-GM-CSFRα antibody disrupted the ability of GM-CSF to polarize CD14+ monocytes into functional MDSCs, rescuing MDSC-mediated T cell suppression in the in vitro proliferation assay. On the other hand, the conditional medium of KRAS wild-type cervical cancer cell line (HeLa), which does not express GM-CSF, did not induce functional MDSCs.
[0221] Mixed lymphocyte reactions were performed using pancreatic cancer (CAPAN-1) condition medium as described above. Figure 6B shows the results of the T cell proliferation assay for the percentage of proliferating cells (left panel) and the maximum (MFI)% (signal detection of CFSE dilution in CD4+ or CD8+ cells) by flow cytometry (right panel). As shown in Figure 6B, CM-treated monocytes suppressed T cell proliferation compared to controls, and the addition of recombinant GM-CSF further suppressed T cell proliferation. Treatment with anti-GM-CSFRα antibody (Ab) reduced MDSC-mediated T cell suppression.
[0222] Next, as described above, a mixed lymphocyte reaction (n=2) was performed using colorectal cancer (SW-480) condition medium. In this particular experiment, anti-GM-CSFRα antibody was added to polarized MDSCs on day 0, and anti-PD-L1 antibody (20 μg / mL) was added to MLRs on day 3. Figure 6C shows that PD-L1 blockade on functionally generated MDSCs in vitro blocks their ability to suppress T cell proliferation. In particular, anti-GM-CSFRα was at least as effective as anti-PD-L1 antibody in blocking PD-L1 on MDSCs and reversing the suppressive function of functionally generated MDSCs. These data also suggest that PD-L1 expression associated with GM-CSF-dependent polarization of CD14+ monocytes to MDSCs is functionally important in suppressing the antitumor immunological response.
[0223] Example 6. KRAS-mutated cancer cell condition medium polarizes monocytes to phenotypic MDSCs. This study demonstrates that human monocytes cultured in a conditional medium from KRAS-mutated cancer cells expressing GM-CSF are polarized to phenotypic MDSCs.
[0224] To generate KRAS-mutated tumor condition medium (CM), cell lines were seeded and cultured according to methods known in the art. CD14+ monocytes were incubated for 3 days with either a basal medium or a condition medium derived from KRAS-mutated cancer cells, followed by phenotypic analysis (HLA-DR, CD11b, and PD-L1) by flow cytometry, as shown in Figure 7A. Low levels of the HLA-DR biomarker indicate the MDSC phenotype. The representative histogram overlay in Figure 7B shows decreased HLA-DR expression and increased CD11b and PD-L1 expression. Similarly, relative expression plotted as geometric mean fluorescence intensity (gMFI) shows decreased HLA-DR expression and increased CD11b and PD-L1 expression when CD14+ monocytes were incubated in condition medium from KRAS-mutated cancer cells compared to CD+14 cells cultured in basal medium (Figure 7C). The results indicate that human monocytes cultured in a conditional medium from GM-CSF-expressing KRAS-mutated cancer cells are polarized to phenotypic MDSCs, as shown by decreased HLA-DR expression and increased CD11b and PD-L1 expression.
[0225] Example 7. The anti-GM-CSFRα antibody inhibits PD-L1 expression associated with the polarization of monocytes into phenotypic MDSCs in vitro. This case study demonstrates that GM-CSF antagonists are sufficient to suppress PD-L1 expression on monocytes treated with conditional medium (CM) from KRAS-mutated cancer cell lines. In particular, low doses of GM-CSF antagonists (e.g., 0.1 μg / mL) were sufficient to achieve this effect.
[0226] As shown in Example 6, the addition of conditional medium from a KRAS-mutated cancer cell line to CD14+ monocytes increased the level of PD-L1 expression compared to baseline (basic medium only). In this study, the effect of anti-GM-CSFRα antibodies on PD-L1 expression was investigated at various concentrations.
[0227] Conditioned media from KRAS mutant cancer cell lines containing GM-CSF (SW-480 and CAPAN-1), or conditioned media from cancer cell lines without GM-CSF (HeLa), were added to CD14+ monocytes containing anti-GM-CSFRα antibody at various concentrations (0.1 μg / mL, 1.0 μg / mL, 10.0 μg / mL, or 100 μg / mL). Basal media and conditioned media without anti-GM-CSFRα antibody were used as controls. After 3 days of incubation, MDSC cells were analyzed for the expression of PD-L1.
[0228] Figure 8A shows that anti-GM-CSFRα antibody blocked the upregulation of PD-L1 and inhibited its polarization into phenotypic MDSC in human monocytes cultured with conditioned media from colorectal (SW-480) and pancreatic (CAPAN-1) KRAS mutant cancer cells expressing GM-CSF. In particular, anti-GM-CSFRα antibody blocked the upregulation of PD-L1 even at a concentration of 0.1 μg / mL. Conditioned media from low GM-CSF expressing human cervical cancer cell line (HeLa) did not induce phenotypic MDSC with PD-L1 expression (Figure 8B).
[0229] Example 8. GM-CSF antagonist inhibits tumor growth in vivo The study of this example shows that GM-CSF antagonist can inhibit tumor growth and provide survival advantage in vivo.
[0230] [[ID=十三]] To establish a mouse model of pancreatic cancer mimicking the pathological characteristics of pancreatic cancer, Pan02 cells were subcutaneously transplanted into female C57BL / 6 mice on day 0. On day 6, when the average volume of the tumors reached 100 mm 3 [[ID=p]]When reached, the mice were randomly assigned to six different treatment groups as shown in Table 2.
Table 2
[0231] Group 1 mice were treated with intraperitoneal (IP) injections of a vehicle (negative control) daily, 5 days a week, with a 2-day treatment break, for 2 weeks, and IP injections of an isotype control antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. Group 2 mice were treated with IP injections of a vehicle daily, 5 days a week, with a 2-day treatment break, for 2 weeks, and IP injections of an anti-mPD-1 antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. Group 3 mice were treated with IP injections of an anti-GM-CSFRα antibody every other day for 2 weeks, and IP injections of an isotype control antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. Group 4 mice were treated with IP injections of anti-GM-CSFRα antibody daily, 5 days a week, with a 2-day treatment break, for 2 weeks, and also with IP injections of isotype control antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. Group 5 mice were treated with IP injections of anti-GM-CSFRα antibody every other day for 2 weeks, and also with IP injections of anti-mPD-1 antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. Group 6 mice were treated with IP injections of anti-GM-CSFRα antibody daily, 5 days a week, with a 2-day treatment break, for 2 weeks, and also with IP injections of anti-mPD1 antibody twice a week, every 3 days, with a 3-day treatment break, for 2 weeks. As shown in Table 2, the following doses were used for all treatment groups: anti-GM-CSFRα antibody at 20 mg / kg, isotype control antibody at 10 mg / kg, anti-mPD-1 antibody at 10 mg / kg, and vehicle at 0.2 mL / 20 g.
[0232] Tumor measurements were performed every other day throughout the study. The primary endpoints of this study were delayed tumor growth and overall survival.
[0233] Inhibition of tumor growth To investigate whether anti-GM-CSFRα antibodies inhibit tumor growth in pancreatic cancer mice, the tumor volume of each mouse was measured 3 and 12 days after the end of treatment and plotted as shown in Figures 9A and 9B, respectively. In Figure 9A, treatment with anti-GM-CSFRα antibodies alone or in combination with other antibodies showed improved directionality in tumor growth inhibition (Groups 3, 4, and 5 vs. Group 1). Furthermore, combination therapy with anti-GM-CSFRα antibodies administered daily for 5 days and 2 weeks together with anti-mPD-1 antibodies (Group 6) resulted in statistically significant tumor growth inhibition compared to the control (Group 1) and monotherapy (Groups 2, 3, and 4). Figure 9B also shows a similar trend when tumor volume is measured 12 days after the end of treatment.
[0234] survival advantage To investigate whether anti-GM-CSFRα antibodies provide a survival advantage in mice with pancreatic cancer, the tumor volume of each mouse was measured on the indicated days, as shown in Figure 10. 3 When it exceeded 2000mm, the mice were slaughtered. 3 The time required to reach the above tumor volume was evaluated and plotted using a Kaplan / Meier plot as shown in Figure 10. 3 The time to reach the above stage was longer in groups 3 and 4, which were treated with anti-GM-CSFRα antibody alone, compared to the control group (group 1) or group 2, which was treated with anti-mPD-1 antibody alone. Furthermore, when the tumor volume reached 2000 mm³... 3 The time to reach the above stage was longer in Group 6, which was treated with anti-GM-CSFRα antibody for 5 days, 2 weeks, daily, and anti-mPD-1 antibody, compared to the control group (Group 1) or Group 2, which was treated with anti-mPD-1 antibody alone. Overall, the data indicate that treatment with anti-GM-CSFRα antibody alone, or in combination with anti-PD1, provides a survival advantage compared to the control or treatment with anti-PD1 antibody alone.
[0235] Equivalents Those skilled in the art will be able to recognize or confirm many equivalents to the specific embodiments of the present invention described herein using ordinary experiments themselves. The scope of the present invention is not intended to be limited to the foregoing, but rather as defined in the following claims.
Claims
1. A composition comprising a GM-CSF antagonist for use in a method of enhancing an immune response to cancer treatment in a patient undergoing cancer treatment, wherein the patient has a cancer having one or more mutations in KRAS, NRAS, PTPN11, and / or JAK2, and wherein the immune response is increased compared to a control.
2. the cancer having one or more mutations in KRAS, NRAS, PTPN11, and / or JAK2, (a) chronic myelomonocytic leukemia (CMML), or (b) Juvenile myelomonocytic leukemia (JMML) 2. The composition for use according to claim 1, wherein
3. The immune response is a percentage of T cell proliferation, and / or the control is (a) indicative of the level of immune response in the patient prior to administration of the GM-CSF antagonist; or (b) a reference immune response level in a control patient undergoing said cancer treatment without a GM-CSF antagonist, or a reference immune response level based on historical data; A composition for use according to claim 1 or 2.
4. A composition for use according to any one of claims 1 to 3, wherein administering the composition to the patient suppresses PD-L1 compared to a control.
5. administering the composition reduces the level of PD-L1 in the patient, and / or the control (a) indicating the PD-L1 level in the patient prior to administration of the GM-CSF antagonist; or (b) a reference PD-L1 level in a control patient undergoing said cancer treatment without a GM-CSF antagonist, or a reference PD-L1 level based on historical data; Optionally, the level of PD-L1 in the patient is decreased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% compared to the control; Optionally, the PD-L1 is expressed on myeloid-derived suppressor cells (MDSCs), e.g., on circulating MDSCs or on plasma-derived MDSCs. A composition for use according to claim 4.
6. The patient, (a) have circulating MDSCs; and / or (b) the patient has a cancer with low levels of infiltrating T cells; and / or (c) suffering from immune checkpoint inhibitor (ICI) refractory cancer, and / or (d) suffering from terminal or metastatic cancer; and / or (e) suffering from a cancer selected from non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, colon adenocarcinoma, rectal adenocarcinoma, endometrial cancer, adenocarcinoma, appendix adenocarcinoma, acute myeloid leukemia, breast cancer, or ovarian cancer, optionally suffering from a cancer selected from non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or pancreatic cancer; A composition for use according to any one of the preceding claims.
7. the method further comprises administering to the patient at least one other cancer therapy, optionally wherein the at least one other cancer therapy is chemotherapy, MDSC targeted therapy, immunotherapy, immune checkpoint inhibitor (ICI) therapy, radiation therapy, and combinations thereof; and / or (a) the composition and the other cancer therapy are administered simultaneously or sequentially; or (b) the patient has been treated with the other cancer therapy prior to said administration of the composition; or (c) the patient has been treated with the composition prior to the administration of the other cancer therapy; A composition for use according to any one of the preceding claims.
8. The other cancer therapy, (a) ICI therapy, optionally (i) the ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, or A2aR; or (ii) the ICI is selected from an anti-PD-1 antibody (optionally pembrolizumab, nivolumab, cemiplimab), an anti-PD-L1 antibody (optionally atezolizumab, avelumab, durvalumab), an anti-CTLA-4 antibody (optionally ipillimumab), an anti-PD-L2 antibody, an anti-B7-H3 antibody, an anti-B7-H4 antibody, an anti-BTLA antibody, an anti-HVEM antibody, an anti-TIM-3 antibody, an anti-GAL-9 antibody, an anti-LAG3 antibody, an anti-VISTA antibody, an anti-KIR antibody, an anti-2B4 antibody, an anti-CD160 antibody, an anti-CGEN-15049 antibody, an anti-CHK1 antibody, an anti-CHK2 antibody, an anti-A2aR antibody, an anti-B-7 antibody, and combinations thereof; or (iii) the ICI is an anti-PD-L1 antibody; or (b) chemotherapy, wherein the patient is administered a chemotherapeutic agent; or (c) an MDSC-targeted therapy, wherein the MDSC-targeted therapy is selected from an anti-CFS-1R antibody, an anti-IL-6 antibody, all-trans retinoic acid, axitinib, entinostat, gemcitabine, or phenformin, and combinations thereof; or (d) immunotherapy, wherein the immunotherapy is selected from a monoclonal antibody, a cytokine, a cancer vaccine, a T cell engaging therapy, and a combination thereof; and optionally, (i) the monoclonal antibody is selected from an anti-CD3 antibody, an anti-CD52 antibody, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, an anti-CD20 antibody, an anti-BCMA antibody, a bispecific antibody, or a bispecific T cell engager (BiTE) antibody, and combinations thereof; or (ii) the cytokine is selected from IFNα, IFNβ, IFNγ, IFN, IL-2, IL-7, IL-15, IL-21, IL-11, IL-12, IL-18, hGM-CSF, TNFα, or any combination thereof; A composition for use according to claim 7.
9. The GM-CSF antagonist is (a) an anti-GM-CSF antibody or fragment thereof, optionally wherein the GM-CSF antagonist is a monoclonal antibody, optionally selected from the group consisting of namilumab, otilimab, lenzilumab, gimsilumab, and TJM2; or (b) a soluble GM-CSF receptor; or (c) an anti-GM-CSF receptor antibody or a fragment thereof, optionally wherein the anti-GM-CSF receptor antibody or a fragment thereof is an anti-GM-CSFRα antibody or a fragment thereof, optionally wherein the anti-GM-CSFRα antibody or a fragment thereof is a monoclonal antibody specific for human GM-CSFRα, optionally wherein the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody, optionally wherein the anti-GM-CSFRα antibody is mavrilimumab, optionally wherein the anti-GM - a CSFRα antibody or fragment thereof comprising a light chain complementarity determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementarity determining region 2 (LCDR2) defined by SEQ ID NO:7 and a light chain complementarity determining region 3 (LCDR3) defined by SEQ ID NO:8, and a heavy chain complementarity determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementarity determining region 2 (HCDR2) defined by SEQ ID NO:4 and a heavy chain complementarity determining region 3 (HCDR3) defined by SEQ ID NO:5, A composition for use according to any one of the preceding claims.
10. said administering said composition and / or said ICI comprising: (a) resulting in a decrease in the level of MDSCs in said patient compared to a control; and / or (b) resulting in a reduced level of MDSC-mediated immunosuppressive activity in said patient compared to a control; and / or (c) resulting in a decrease in the percentage of Lin − CD14 + HLA-DR − M-MDSCs in the peripheral blood of said patient compared to a control; and / or (d) resulting in an increased percentage of mature MDSC cells in said patient compared to a control; and / or (e) resulting in reduced levels of Treg cells, macrophages, and / or neutrophils compared to a control; and / or (f) resulting in a decrease in the level of an inhibitory cytokine, optionally wherein the inhibitory cytokine is selected from IL-10 and TGFβ; and / or (g) resulting in a decrease in the level of an immunosuppressive factor, optionally wherein the immunosuppressive factor is selected from arginase 1, inducible nitric oxide synthase (iNOS), peroxynitrite, nitric oxide, reactive oxygen species, tumor associated macrophages, and combinations thereof; and / or (h) resulting in an increase in the level of CD4 + T effector cells compared to a control, optionally wherein said control is a pre-treatment level or percentage in said patient, or a reference level or percentage based on historical data; A composition for use according to any one of the preceding claims.
11. The composition, (a) administered at between 2 mg / kg and 10 mg / kg of said GM-CSF antagonist, optionally at 3 mg / kg of said GM-CSF antagonist, at 6 mg / kg of said GM-CSF antagonist, or at 10 mg / kg of said GM-CSF antagonist; and / or (b) administered once every other week; A composition for use according to any one of the preceding claims.
12. 2. A composition for use according to any one of the preceding claims, wherein the time to transformation to acute myeloid leukemia (AML) is shortened.
13. A pharmaceutical composition for use in a method for treating cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, comprising a GM-CSF antagonist and an ICI.
14. A kit for treating a cancer having one or more mutations in KRAS, NRAS, JAK2, and / or PTPN11, comprising: (a) a GM-CSF antagonist; (b) a pharmaceutical composition comprising at least one other cancer therapy selected from chemotherapy, MDSC targeted therapy, immunotherapy, radiation therapy, and combinations thereof; A kit comprising a pharmaceutical composition comprising:
15. The GM-CSF antagonist is (a) an anti-GM-CSF antibody or fragment thereof, optionally wherein the GM-CSF antagonist is a monoclonal antibody, optionally selected from the group consisting of namilumab, otilimab, lenzilumab, gimsilumab, and TJM2; or (b) a soluble GM-CSF receptor; or (c) an anti-GM-CSF receptor antibody or a fragment thereof, optionally wherein the anti-GM-CSF receptor antibody or a fragment thereof is an anti-GM-CSFRα antibody or a fragment thereof, optionally wherein the anti-GM-CSFRα antibody or a fragment thereof is a monoclonal antibody specific for human GM-CSFRα, optionally wherein the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody, optionally wherein the anti-GM-CSFRα antibody is mavrilimumab, optionally wherein the anti-GM - a CSFRα antibody or fragment thereof comprising a light chain complementarity determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementarity determining region 2 (LCDR2) defined by SEQ ID NO:7 and a light chain complementarity determining region 3 (LCDR3) defined by SEQ ID NO:8, and a heavy chain complementarity determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementarity determining region 2 (HCDR2) defined by SEQ ID NO:4 and a heavy chain complementarity determining region 3 (HCDR3) defined by SEQ ID NO:5, A pharmaceutical composition for the use according to claim 13 or a kit for the use according to claim 14.
16. The ICI is (a) antagonizing the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, and combinations thereof; and / or (b) an anti-PD-1 antibody (optionally pembrolizumab, nivolumab, cemiplimab), an anti-PD-L1 antibody (optionally atezolizumab, avelumab, durvalumab), an anti-CTLA-4 antibody (optionally ipilimumab), an anti-PD-L2 antibody, an anti-B7-H3 antibody, an anti-B7-H4 antibody, an anti-BTLA antibody, an anti-HVEM antibody, an anti-TIM-3 antibody, an anti-GAL-9 antibody, an anti-LAG3 antibody, an anti-VISTA antibody, an anti-KIR antibody, an anti-2B4 antibody, an anti-CD160 antibody, an anti-CGEN-15049 antibody, an anti-CHK1 antibody, an anti-CHK2 antibody, an anti-A2aR antibody, an anti-B-7 antibody, and combinations thereof; A pharmaceutical composition for the use according to claim 13 or a kit for the use according to claim 14.
